Compound used for EGFR protein degradation, and use thereof

By developing a compound with excellent EGFR degradation performance, the problem of drug resistance mutation of EGFR targeting agents has been solved, and effective treatment of EGFR-related diseases, especially non-small cell lung cancer has been achieved.

WO2024235289A1PCT designated stage expired Publication Date: 2024-11-21TYK MEDICINES INC
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/093652
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-05-16
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing EGFR targeting agents are prone to drug resistance mutation problems in clinical applications, especially EGFRT790M and EGFRC797S drug resistance mutations, resulting in reduced therapeutic effects. The existing EGFR degrading agents have limited effects, and new EGFR protein regulatory drugs are needed to overcome them. Drug resistance.

Method used

A novel compound is provided for the preparation of compounds with excellent EGFR degradation properties through structural optimization for the prevention and treatment of EGFR-related diseases, especially non-small cell lung cancer associated with drug resistance mutations.

Benefits of technology

Compounds have excellent inhibitory and therapeutic effects on EGFR-related diseases, especially EGFR-resistant mutation diseases, and have excellent pharmacokinetic performance and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024093652_21112024_PF_FP_ABST
    Figure CN2024093652_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a compound used for EGFR protein degradation, and a use thereof. Specifically, the compound of the present invention has a structure as shown in formula I, wherein the definition of each group and substituent is as described in the description. Further disclosed are a method for preparing the compound, and a use of the compound in the prevention and / or treatment of EGFR-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Compounds for EGFR protein degradation and uses thereof Technical Field

[0001] The present invention relates to the field of medical technology, in particular to a compound for EGFR protein degradation and a use thereof. Background Art

[0002] The HER family of receptor tyrosine kinases is a mediator of cell growth, differentiation, and survival. This receptor family includes four different members, namely the epidermal growth factor receptor (EGFR, ErbB1 or HER1), HER2 (ErbB2), HER3 (ErbB3), and HER4 (ErbB4). After ligand binding, the receptor forms homodimers or heterodimers, and subsequent activation of endogenous tyrosine kinase activity leads to receptor autophosphorylation and activation of downstream signaling molecules. It has been shown that the regulation of EGFR activation caused by overexpression or mutation is involved in many types of human cancers including colorectal cancer, pancreatic cancer, glioma, head and neck cancer, and lung cancer, especially non-small cell lung cancer (NSCLC). Over the years, a variety of EGFR-targeted agents have been developed, and three generations of drugs are already in clinical use.

[0003] In actual clinical applications, patients typically develop EGFR T790M resistance mutations 8-12 months after using first- or second-generation EGFR inhibitors, causing the drugs to lose their therapeutic effectiveness. Although later-released third-generation EGFR inhibitors, such as osimertinib and ametinib, can effectively overcome EGFR T790M resistance, resistance mutations such as EGFR C797S can still appear after a period of use, leading to disease progression.

[0004] The problem of mutation resistance that frequently occurs during the treatment with EGFR small molecule tyrosine kinase inhibitors has become a difficult problem that needs to be solved urgently in clinical practice. Although some EGFR allosteric inhibitor compounds, such as EAI045, have been reported to overcome C797S resistance, the clinical effect is limited. In recent years, some patents (WO2019149922, WO2021127561) have reported that a series of PROTAC-type compounds can overcome the resistance problem of C797S by degrading EGFR protein, which has become a new research direction. Although some progress has been made in EGFR allosteric inhibitors and EGFR degraders, there is still a need to find more clinically valuable EGFR protein regulating drugs for the treatment of diseases caused by current EGFR disorders, especially in the field of EGFR-positive non-small cell lung cancer.

[0005] Summary of the Invention

[0006] The object of the present invention is to provide a compound represented by formula I and its use in preventing and / or treating EGFR-related diseases.

[0007] The first aspect of the present invention provides a compound, which is a compound represented by Formula I, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotope compound or prodrug thereof,

[0008] in:

[0009] L is selected from the following group:

[0010] Ring A is selected from the group consisting of:

[0011] Ring B is selected from the group consisting of:

[0012] Among various

[0013] Each X1 and X2 are independently selected from the following group: CR, N;

[0014] Each X3 is independently selected from the group consisting of NH, O, and none;

[0015] Each Ar is independently selected from the group consisting of substituted or unsubstituted phenyl, substituted or unsubstituted 5-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S, The substitution refers to substitution by one or more (such as 2, 3 or 4) substituents selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, hydroxy substituted C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl-NH-, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 3-6 Halogenated cycloalkyl, cyano, oxo, -C(O)NR9R 10 、-CO-C 1-6 Alkyl, -CO-C 3-6 Cycloalkyl, -CO-C 1-6 Haloalkyl, -CO-C 3-6 Halogenated cycloalkyl, 5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S;

[0016] Each R1 is independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl, cyano;

[0017] Each R2, R3 is independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkyl-NH-, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Halogenated alkyl, cyano, C3 -6 Halogenated cycloalkyl, -NR9C(O)R 10 、-C(O)NR9R 10 , methylsulfonyl, Unsubstituted or C 1-6 an alkyl-substituted 5-10 membered heteroaryl group containing 1, 2 or 3 heteroatoms selected from N, O or S;

[0018] Each R4 is independently selected from the group consisting of: C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl;

[0019] Each R5 is independently selected from the group consisting of: absent, C 1-6 Alkyl, NR,

[0020] Each R6, R7, R8 is independently selected from the following group: H, halogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl-NH-, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Haloalkyl, cyano, C 3-6 Halogenated cycloalkyl-NR9C(O)R 10 、-C(O)NR9R 10 , methylsulfonyl, Hydroxyl, or R6 and the ring to which it is connected form a 3-6 membered ring;

[0021] Each R9 is independently selected from the group consisting of H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl;

[0022] Each R 10Independently selected from the group consisting of H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Halogenated alkyl, C 3-6 Halogenated cycloalkyl, methylsulfonyl,

[0023] Each m, n, q is independently selected from the following group: 0, 1, 2, 3, 4, 5;

[0024] Each R 11 Independently selected from the group consisting of H, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl;

[0025] Each R is independently selected from the group consisting of H, C 1-6 Alkyl, hydroxyl, halogen, C 1-6 Halogenated alkyl.

[0026] In another preferred embodiment, at least one of X1 and X2 is N.

[0027] In another preferred embodiment, the 5-10 membered heteroaryl group containing 1, 2 or 3 heteroatoms selected from N, O or S is selected from the following group: pyridyl Thiazolyl Indolyl Quinolinyl

[0028] In another preferred embodiment, the 5-6 membered heteroaryl group containing 1, 2 or 3 heteroatoms selected from N, O or S is selected from the following group:

[0029] In another preferred embodiment, each Ar is independently selected from the following groups: substituted phenyl, The substitution refers to substitution by a substituent selected from the group consisting of: -C(O)NR9R 10 , a 5-6 membered heteroaryl group containing 1, 2 or 3 N atoms;

[0030] R 11 ,q as defined in claim 1;

[0031] R9 is selected from the group consisting of H, C 1-6 alkyl;

[0032] R 10 Selected from the following group: H, C 1-6alkyl;

[0033] And R9 and R 10 Not H at the same time.

[0034] In another preferred embodiment, each Ar is independently selected from the following groups: substituted phenyl, The substitution refers to substitution by a substituent selected from the group consisting of: -C(O)NR9R 10 , a 5-6 membered heteroaryl group containing 1, 2 or 3 N atoms;

[0035] R 11 ,q as defined in claim 1;

[0036] R9 is H;

[0037] R 10 C 1-6 alkyl.

[0038] In another preferred embodiment, R9 and R 10 One is H and the other is C 1-6 Alkyl (preferably C 1-3 alkyl, more preferably C1 alkyl).

[0039] In another preferred embodiment, R9 and R 10 One is H and one is C selected from the following group 1-6 Alkyl: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, neopentyl, tert-pentyl, hexyl.

[0040] In another preferred embodiment, Ar is a substituted phenyl group, wherein the substitution is -C(O)NR9R 10 replace.

[0041] In another preferred embodiment, X1 and X2 are both N; or one of X1 and X2 is N and the other is CR.

[0042] In another preferred embodiment, in L, X1 is N, and X2 is CR.

[0043] In another preferred embodiment, in L, X1 is CR, and X2 is N.

[0044] In another preferred embodiment, in L, X1 is N, and X2 is N.

[0045] In another preferred embodiment, in ring B, X1 is CR and X2 is CR.

[0046] In another preferred embodiment, in ring B, X1 is CR, and X2 is N. In another preferred embodiment, R1 is selected from the following group: hydrogen, halogen, trifluoromethyl, and cyano.

[0047] In another preferred embodiment, R1 is a halogen selected from the group consisting of F, Cl, Br, and I.

[0048] In another preferred embodiment, R2 is H.

[0049] In another preferred embodiment, R3 is selected from the following group: H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl.

[0050] In another preferred embodiment, R3 is selected from the following group: C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl.

[0051] In another preferred embodiment, R3 is C selected from the group consisting of 1-6 Alkyl: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, neopentyl, tert-pentyl, hexyl.

[0052] In another preferred embodiment, the compound is a compound represented by Formula II, Formula III, Formula IV, Formula V, Formula VI or Formula VII,

[0053] Wherein, R4 is C selected from the group consisting of 1-6 Alkyl: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, neopentyl, tert-pentyl, hexyl.

[0054] In another preferred embodiment, R6 forms a 3-6 membered ring with the ring to which it is connected, thereby forming a spiro ring, a fused ring or a bridged ring. Preferably, R6 is C 1-4 Alkylene, and with the connected ring to form More preferably, R6 is methylene;

[0055] Wherein, X1 and X2 are as defined above.

[0056] In another preferred embodiment, the compound is selected from the following group:

[0057] In another preferred embodiment, the pharmaceutically acceptable salt is an inorganic acid salt or an organic acid salt;

[0058] The inorganic acid salt is selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, nitrate, phosphate, and acid phosphate;

[0059] The organic acid salt is selected from the group consisting of formate, acetate, trifluoroacetate, propionate, pyruvate, glycolate, oxalate, malonate, fumarate, maleate, lactate, malate, citrate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, salicylate, picrate, glutamate, ascorbate, camphorate, and camphorsulfonate.

[0060] In another preferred embodiment, the compound is not a compound selected from the following group:

[0061] In another preferred embodiment, the compound is not a compound selected from the following group:

[0062] The second aspect of the present invention provides a pharmaceutical composition comprising a safe and effective amount of the compound described in the first aspect of the present invention and a pharmaceutically acceptable carrier.

[0063] In another preferred embodiment, the pharmaceutical composition further comprises a second active ingredient selected from the group consisting of gefitinib, erlotinib, icotinib, lapatinib, XL647, NVP-AEE-788, ARRY-334543, vandetanib, PF00299804, cetuximab, panitumumab, pertuzumab, zalutumumab, nimotuzumab, MDX-214, CDX-110, IMC-11F8, CNF2024, tanspiramycin, aspiramycin, IPI-504, and NVP-AUY922.

[0064] The third aspect of the present invention provides a use of the compound according to the first aspect of the present invention, for use selected from the group consisting of:

[0065] 1) Preparation of drugs for regulating EGFR kinase activity or treating EGFR-related diseases;

[0066] 2) Preparation of drugs for degrading EGFR protein.

[0067] In another preferred embodiment, the EGFR-related disease is an EGFR drug-resistant mutation-related disease.

[0068] In another preferred embodiment, the EGFR drug-resistant mutation is selected from the following group: EGFR T790M, EGFR C797S, T780M, C797S, DEL19, L858R, DEL19 / T790M, DEL10 / T790M / C797S, L858R / T790M / C797S, or a combination thereof.

[0069] In another preferred embodiment, the EGFR-related disease is selected from the following group: inflammation, cancer, cardiovascular disease, infection, immune disease, and metabolic disease.

[0070] In another preferred embodiment, the cancer is selected from the following group: lung cancer (including lung adenocarcinoma, non-small cell lung cancer), breast cancer, prostate cancer, colorectal cancer, liver cancer, pancreatic cancer, ovarian cancer, leukemia, neuroblastoma, gastric cancer, kidney cancer, esophageal cancer, uterine cancer, glioma, head and neck cancer.

[0071] In another preferred embodiment, the EGFR-related disease is non-small cell lung cancer with an EGFR mutation selected from the group consisting of T790M / L858R, T790M / L858R / C797S, L858R, and L858R / C797S.

[0072] A fourth aspect of the present invention provides a method for preventing and / or treating diseases associated with EGFR drug-resistant mutations, comprising the steps of:

[0073] 1) Determine the patient's EGFR activating mutation status;

[0074] 2) If the patient's EGFR activating mutation status meets the treatment conditions, administering the compound of the first aspect of the present invention to the patient.

[0075] In another preferred example, the patient's EGFR activating mutation status meeting the treatment conditions means that the patient has an EGFR mutation selected from the following group: T790M / L858R, T790M / L858R / C797S, L858R, L858R / C797S.

[0076] In another preferred embodiment, the EGFR resistance mutation-related disease is selected from the following group: lung cancer (including lung adenocarcinoma, non-small cell lung cancer), breast cancer, prostate cancer, colorectal cancer, liver cancer, pancreatic cancer, ovarian cancer, leukemia, neuroblastoma, gastric cancer, kidney cancer, esophageal cancer, uterine cancer, glioma, head and neck cancer.

[0077] In another preferred embodiment, the EGFR drug-resistant mutation-related disease is non-small cell lung cancer.

[0078] In another preferred embodiment, the “determining the patient's EGFR activating mutation status” is determined by the cobas EGFR mutation assay v2.

[0079] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS

[0080] FIG1 is a schematic diagram of the cell preparation steps of Experimental Example 2.

[0081] FIG2 is a schematic diagram of the detection steps of Experimental Example 2. DETAILED DESCRIPTION

[0082] After extensive and in-depth research, the inventors unexpectedly developed a compound with excellent EGFR degradation properties through structural optimization. This compound exhibits excellent inhibitory and / or therapeutic effects against EGFR-related diseases (particularly diseases associated with EGFR drug-resistant mutations), and also exhibits excellent pharmacokinetic properties. Based on this, the inventors completed the present invention.

[0083] the term

[0084] In the present invention, unless otherwise specified, the terms used have the general meanings commonly known to those skilled in the art.

[0085] When a substituent is described by a conventional chemical formula written from left to right, the substituent also includes chemically equivalent substituents that would result if the formula were written from right to left. For example, -CH2O- is equivalent to -OCH2-.

[0086] "Alkyl (alone or as part of another group)" refers to a monovalent straight or branched chain saturated hydrocarbon group containing 1 to 12 carbon atoms consisting solely of carbon and hydrogen atoms. Alkyl is preferably a C1-C6 alkyl (i.e., containing 1, 2, 3, 4, 5, or 6 carbon atoms). Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl, n-hexyl, octyl, dodecyl, and the like. In this application, alkyl is also intended to include substituted alkyls, i.e., one or more positions in the alkyl group are substituted, particularly 1-4 substituents, which may be substituted at any position. "Haloalkyl" refers to an alkyl as defined herein in which one or more hydrogens are replaced by the same or different halogens. Examples of haloalkyls include -CH2Cl, -CH2CF3, -CH2CCl3, perfluoroalkyls (e.g., -CF3), and the like.

[0087] "Alkylene" refers to a divalent radical of an alkyl group, for example, -CH2-, -CH2CH2-, and -CH2CH2CH2-.

[0088] "Alkoxy (alone or as part of another group)" refers to an alkyl group having an oxy group attached thereto, having an alkylO- structure, wherein alkyl has the definition described above. Preferably, alkoxy is a C1-C6 alkoxy group. Alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, tert-butoxy, and the like. "Haloalkoxy" refers to a group of the formula -OR, where R is a haloalkyl group as defined herein. Examples of haloalkoxy groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, 2,2,2-trifluoroethoxy, and the like.

[0089] "Alkenyl (alone or as part of another group)" refers to an aliphatic group containing at least one double bond, typically having 2 to 20 carbon atoms. In the present invention, "C2-C6 alkenyl" refers to an alkenyl group containing 2, 3, 4, 5 or 6 carbon atoms. Alkenyl includes, but is not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, etc. In the present invention, alkenyl includes substituted alkenyl.

[0090] "Alkenylene" refers to an alkenyl group with two points of attachment. For example, "vinylene" refers to the group -CH=CH-. Alkenylene can also be unsubstituted or substituted with one or more substituents.

[0091] "Alkynyl (alone or as part of another group)" refers to a straight or branched hydrocarbon chain containing two or more carbon atoms and characterized by one or more triple bonds, typically having 2 to 20 carbon atoms. In the present invention, "C2-6 alkynyl" refers to an alkynyl group having 2, 3, 4, 5, or 6 carbon atoms. Alkynyl groups include, but are not limited to, ethynyl, propargyl, and 3-hexynyl. One of the triple bond carbons may optionally be the point of attachment for an alkynyl substituent. In the present invention, alkynyl groups also include substituted alkynyl groups.

[0092] "Alkynylene" refers to an alkynyl group with two points of attachment. For example, "ethynylene" refers to the group: -C≡C-. Alkynylene groups can be unsubstituted or substituted with one or more substituents.

[0093] "Cycloalkyl" refers to a monovalent saturated carbocyclic group consisting of a mono- or bicyclic ring having 3-12, preferably 3-10, and more preferably 3-8 ring atoms. A cycloalkyl group may be optionally substituted with one or more substituents, each of which is independently hydroxy, alkyl, alkoxy, halogen, haloalkyl, amino, monoalkylamino, or dialkylamino. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.

[0094] "Cycloalkyloxy" refers to a radical of the formula -OR, where R is a cycloalkyl radical as defined herein. Exemplary cycloalkyloxy radicals include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like. "Cycloalkylalkyl" refers to a -(cycloalkyl)-alkyl radical where the cycloalkyl and alkyl radicals are as disclosed herein. "Cycloalkylalkyl" is bonded to the parent molecular structure through the cycloalkyl radical.

[0095] "Heteroaryl" refers to a monocyclic (e.g., 5- or 6-membered), bicyclic (e.g., 8-10-membered) or tricyclic group of 5 to 12 ring atoms, which contains at least one aromatic ring containing 1, 2 or 3 ring heteroatoms selected from N, O or S, the remaining ring atoms being C, it being understood that the point of attachment of the heteroaryl group should be on the aromatic ring. Examples of heteroaryl groups include, but are not limited to, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, thienyl, furanyl, pyranyl, pyridinyl, pyrrolyl, pyrazolyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuranyl, benzofuranyl, benzothienyl, benzothiopyranyl, benzimidazolyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzopyranyl, indolyl, isoindolyl, triazolyl, triazinyl, quinoxalinyl, purinyl, quinazolinyl, quinolizinyl, naphthyridinyl, pteridinyl, carbazolyl, aza Base, diazepine A heteroarylene group refers to a heteroaryl group having two attachment sites.

[0096] "Heterocyclic ring system" refers to monocyclic, bicyclic, and polycyclic ring systems in which at least one ring is saturated or partially unsaturated (but non-aromatic) and the ring contains at least one heteroatom. The heterocyclic ring system may be attached to a pendant group at any heteroatom or carbon atom that creates a stable structure and any ring atom may be optionally substituted.

[0097] "Heterocyclyl" refers to a monovalent radical of a heterocyclic ring system, generally a stable monocyclic ring (e.g., 3-8 members, i.e., 3-membered, 4-membered, 5-membered, 6-membered, 7-membered or 8-membered) or bicyclic ring (e.g., 5-12 members, i.e., 5-membered, 6-membered, 7-membered, 8-membered, 9-membered, 10-membered, 11-membered or 12-membered) or polycyclic ring (e.g., 7-14 members, i.e., 7-membered, 8-membered, 9-membered, 10-membered, 11-membered, 12-membered, 13-membered or 14-membered), including fused, spiro and / or bridged ring structures, which are saturated, partially unsaturated, and which contain carbon atoms and 1, 2, 3 or 4 heteroatoms independently selected from N, O and S. Representative heterocyclyl groups include ring systems in which (1) each ring is non-aromatic and at least one ring contains a heteroatom, for example, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl; (2) at least one ring is Non-aromatic and containing heteroatoms and at least one other ring is an aromatic carbocyclic ring, for example, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl; and (3) at least one ring is non-aromatic and contains heteroatoms and at least one other ring is aromatic and contains heteroatoms, for example, 3,4-dihydro-1H-pyrano[4,3-c]pyridine and 1,2,3,4-tetrahydro-2,6-naphthyridine. Heterocyclylene refers to a heterocyclyl having two connection sites. In the present invention, preferably, the heterocyclylene is a bicyclic ring, one of which is a heteroaryl group, and is connected to the other parts in the general formula through the heteroaryl group. In the present invention, preferably, the heterocyclylene is a 5-6 membered monocyclic heterocyclylene or an 8-10 membered bicyclic heterocyclylene.

[0098] "Heterocyclylalkyl" refers to an alkyl group substituted with a heterocyclyl group, wherein the heterocyclyl group and the alkyl group are as defined above.

[0099] When a substituent is non-terminal, it is a substituent of the corresponding group, for example, alkyl for alkylene, cycloalkyl for cycloalkylene, heterocyclyl for heterocyclylene, alkoxy for alkyleneoxy, and the like.

[0100] In the present invention, each of the above-mentioned alkyl, alkoxy, cycloalkyl, heteroalkyl, aryl, heteroaryl, cycloheteroalkyl, alkenyl, alkyne, heterocycle, heterocyclyl, etc. may be substituted or unsubstituted.

[0101] In the present invention, the term "substituted" refers to one or more hydrogen atoms on a specific group being replaced by a specific substituent. The specific substituent is the substituent described above, or the substituent appearing in the embodiments. Unless otherwise specified, a substituted group may have a substituent selected from a specific group at any substitutable site of the group, and the substituent may be the same or different at each position. It will be understood by those skilled in the art that the combination of substituents contemplated by the present invention is those that are stable or chemically feasible. Typical substitutions include, but are not limited to, one or more of the following groups: such as hydrogen, deuterium, halogen (e.g., a monohalogen substituent or a polyhalogen substituent, the latter such as a trifluoromethyl group or an alkyl group containing Cl3), cyano, nitro, oxo (such as =O), trifluoromethyl, trifluoromethoxy, cycloalkyl, alkenyl, alkynyl, heterocycle, aromatic ring, OR a SR a 、S(=O)R e 、S(=O)2R e 、P(=O)2R e 、S(=O)2OR e , P(=O)2OR e NR b R c NR b S(=O)2R e NR b P(=O)2R e 、S(=O)2NR b R c 、P(=O)2NR b R c 、C(=O)OR d 、C(=O)R a 、C(=O)NR b R c 、OC(=O)R a 、OC(=O)NR b R c NR b C(=O)OR e NR d C(=O)NR b R c NR d S(=O)2NR b R c NR d P(=O)2NR b R c NR b C(=O)R a , or NR b P(=O)2R e , where Ra R may independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, alkynyl, heterocyclic or aromatic rings. b 、R c and R d may independently represent hydrogen, deuterium, an alkyl group, a cycloalkyl group, a heterocyclic ring or an aromatic ring, or R b and R c Together with the N atom, it can form a heterocyclic ring; R e and alkyl, cycloalkyl, alkenyl, alkynyl, heterocycle, or aromatic ring. The above typical substituents, such as alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aromatic ring, may be optionally substituted. Examples of such substituents include, but are not limited to, halogen, hydroxyl, cyano, carboxyl (-COOH), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3-12 membered heterocyclyl, aryl, heteroaryl, C1-C8 aldehyde, C2-C10 acyl, C2-C10 ester, amine, C1-C6 alkoxy, C1-C10 sulfonyl, and C1-C6 urea.

[0102] "Cyano" refers to a -CN group.

[0103] "Nitro" refers to -NO2.

[0104] "Hydroxyl" refers to -OH.

[0105] "Amino" refers to -NH2 or RNH-, where R is ketocarbonyl, sulfonyl, sulfonamide, R a -C(=O)-, R a R b NC(=O)- etc., where R a and R b is an alkyl group, a cycloalkyl group, an aryl group or a heteroaryl group.

[0106] "Halogen" refers to any halogen radical, for example, -F, -Cl, -Br, or -I.

[0107] "Deuterated compound" refers to a compound in which one or more hydrogen atoms (H) are replaced by deuterium atoms (D).

[0108] In the present invention, the term "plurality" independently refers to 2, 3, 4, or 5.

[0109] Compound

[0110] The present invention provides a compound, which is a compound represented by Formula I, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotope compound or prodrug thereof.

[0111] wherein each group is as defined above.

[0112] In another preferred embodiment, in the compound, any one of the groups is independently the corresponding group in the specific compound.

[0113] As used herein, the term "pharmaceutically acceptable salt" refers to a salt of a compound of the present invention formed with an acid or base that is suitable for pharmaceutical use. Pharmaceutically acceptable salts include inorganic salts and organic salts. A preferred class of salts are salts formed with a compound of the present invention and an acid. Suitable acids for forming salts include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, and naphthalenesulfonic acid; and amino acids such as proline, phenylalanine, aspartic acid, and glutamic acid.

[0114] Another preferred salt is a salt of the compound of the present invention formed with a base, such as an alkali metal salt (e.g., sodium salt or potassium salt), an alkaline earth metal salt (e.g., magnesium salt or calcium salt), an ammonium salt (e.g., lower alkanolammonium salt and other pharmaceutically acceptable amine salts), for example, methylamine salt, ethylamine salt, propylamine salt, dimethylamine salt, trimethylamine salt, diethylamine salt, triethylamine salt, tert-butylamine salt, ethylenediamine salt, hydroxyethylamine salt, dihydroxyethylamine salt, trihydroxyethylamine salt, and amine salts formed from morpholine, piperazine, and lysine, respectively.

[0115] The term "solvate" refers to a complex formed by the coordination of a compound of the present invention with solvent molecules in a specific ratio. "Hydrate" refers to a complex formed by the coordination of a compound of the present invention with water.

[0116] In addition, the compounds of the present invention also include prodrugs of the compounds represented by Formula I. The term "prodrug" includes compounds that may be biologically active or inactive, and that, when administered using appropriate methods, undergo metabolic or chemical reactions in the human body to convert into a compound of Formula I, or a salt or solution of a compound of Formula I. Such prodrugs include (but are not limited to) carboxylate esters, carbonate esters, phosphate esters, nitrate esters, sulfate esters, sulfone esters, sulfoxide esters, amino compounds, carbamates, azo compounds, phosphoramides, glucosides, ethers, acetals, and the like of the compounds.

[0117] The compounds, salts or solvates of the present invention may exist in tautomeric forms (such as amides and imino ethers). All such tautomers are part of the present invention.

[0118] All stereoisomers of the compounds (e.g., those that may exist due to asymmetric carbon atoms for various substitutions), including enantiomeric and diastereomeric forms, are contemplated by the present invention. Individual stereoisomers of the compounds of the present invention may not exist with other isomers (e.g., as a pure or substantially pure optical isomer having a particular activity), or may be mixtures, such as racemates, or mixtures with all other stereoisomers or portions thereof. The chiral centers of the present invention have either S or R configurations, as defined by the 1974 recommendations of the International Union of Pure and Applied Chemistry (IUPAC). Racemic forms can be resolved by physical methods, such as fractional crystallization, or by crystallization of diastereomers derived from them, or by separation by chiral column chromatography. Individual optical isomers can be obtained from the racemate by suitable methods, including but not limited to conventional methods, such as salt formation with an optically active acid followed by recrystallization.

[0119] The compounds of the present invention, obtained by sequential preparation, isolation, and purification, are described in the text to a concentration of 90% or greater by weight, for example, 95% or greater, or 99% or greater ("very pure" compounds). Such "very pure" compounds of the present invention are also considered part of the present invention.

[0120] All configurational isomers of the compounds of the present invention are encompassed, whether in mixture, pure or very pure form. The definition of the compounds of the present invention includes both cis (Z) and trans (I) olefin isomers, as well as cis and trans isomers of carbocyclic and heterocyclic rings.

[0121] Throughout the specification, groups and substituents may be chosen to provide stable fragments and compounds.

[0122] Specific functional groups and chemical term definitions are detailed below. For the purposes of this invention, chemical elements are referred to in the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75 th The definitions of specific functional groups are consistent with those in "Organic Chemistry," Thomas Sorrell, University Science Books, Sausalito, 1999, which is incorporated by reference in its entirety.

[0123] Certain compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention encompasses all compounds, including their cis and trans isomers, R and S enantiomers, diastereomers, (D) isomers, (L) isomers, racemic mixtures, and other mixtures. Additionally, asymmetric carbon atoms may represent substituents, such as alkyl groups. All isomers and mixtures thereof are encompassed by the present invention.

[0124] According to the present invention, mixtures of isomers can contain various ratios of isomers. For example, mixtures containing only two isomers can have the following ratios: 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0. All ratios of isomers are within the scope of the present invention. Similar ratios, as well as ratios for more complex mixtures of isomers, are readily understood by those skilled in the art and are also within the scope of the present invention.

[0125] The present invention also includes isotopically labeled compounds that are equivalent to the original compounds disclosed herein. However, in practice, it is common for one or more atoms to be replaced by atoms having a different atomic mass or mass number. Examples of isotopes of the compounds of the present invention include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine isotopes, such as 2 H. 3 H. 13 C. 11 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 The compounds of the present invention, or enantiomers, diastereomers, isomers, or pharmaceutically acceptable salts or solvates thereof, which contain isotopes or other isotopic atoms of the above compounds are within the scope of the present invention. Certain isotopically labeled compounds of the present invention, such as 3 H and 14 Radioisotopes of C are also included and are useful in tissue distribution experiments of drugs and substrates. 3 H and carbon-14, i.e. 14 C, their preparation and detection are relatively easy. It is the first choice among isotopes. In addition, heavier isotope substitutions such as deuterium, i.e. 2H, due to its excellent metabolic stability, has advantages in certain therapeutics, such as increasing half-life in vivo or reducing dosage, and therefore, may be preferred in some cases. Isotopically labeled compounds can be prepared using conventional methods by replacing readily available isotopically labeled reagents with non-isotopic reagents using the protocols disclosed in the examples.

[0126] If a synthesis of a specific enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, followed by separation of the resulting diastereomeric mixture and removal of the chiral auxiliary to obtain the pure enantiomer. Alternatively, if the molecule contains a basic functional group, such as an amino acid, or an acidic functional group, such as a carboxyl group, diastereomeric salts can be formed with a suitable optically active acid or base, followed by separation by conventional means such as fractional crystallization or chromatography to obtain the pure enantiomer.

[0127] As described herein, the compounds of the present invention may be substituted with any number of substituents or functional groups to expand their scope. Generally, the term "substituted," whether preceded or followed by the term "optionally," in formulas of the present invention including substituents, refers to the replacement of a hydrogen radical with a substituent of the specified structure. When multiple positions in a particular structure are substituted with multiple substituents of the specified structure, the substituents may be the same or different at each position. As used herein, the term "substituted" includes all permissible substitutions in organic compounds. Broadly speaking, permissible substituents include acyclic, cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic organic compounds. For example, heteroatoms of nitrogen may be substituted with hydrogen or any of the permissible organic compounds described above to supplement their valences. Furthermore, the present invention is not intended to limit the permissible substitutions in any way to organic compounds. The present invention recognizes that combinations of substituents and variables are advantageous for providing stable compounds for the treatment of diseases. As used herein, the term "stable" refers to compounds that are stable and maintain the structural integrity of the compound over a period of time sufficient to be detected, preferably over a period of time sufficient to be effective, as used herein for the purposes described above.

[0128] The metabolites of the compounds and pharmaceutically acceptable salts thereof involved in the present application, as well as prodrugs that can be converted into the structures of the compounds and pharmaceutically acceptable salts involved in the present application and in vivo, are also included in the claims of the present application.

[0129] It should be understood that the embodiments of the present invention specifically describe the preparation methods of the compounds of formula I of the present invention, but these specific methods do not constitute any limitation to the present invention. The compounds of the present invention can also be conveniently prepared by optionally combining various synthetic methods described in this specification or known in the art, and such combinations can be easily made by those skilled in the art.

[0130] Typically, the raw materials and reagents used in the process for preparing the compounds of the present invention can be purchased through commercial channels unless otherwise specified.

[0131] Typically, in the preparation process, each reaction is usually carried out under the protection of an inert gas in a suitable solvent at a temperature of 0 to 150° C., and the reaction time is usually 2 to 24 hours.

[0132] Pharmaceutical compositions and methods of administration

[0133] The present invention also provides a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.

[0134] Since the compounds of the present invention have excellent anti-tumor activity, the compounds of the present invention and their various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and pharmaceutical compositions containing the compounds of the present invention as the main active ingredient can be used to treat, prevent and alleviate tumor-related diseases.

[0135] The pharmaceutical composition of the present invention comprises a safe and effective amount of a compound of the present invention or a pharmacologically acceptable salt thereof, and a pharmacologically acceptable excipient or carrier. "Safe and effective amount" means an amount of the compound sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, more preferably 10-1000 mg of the compound of the present invention per dose. Preferably, "one dose" is one capsule or tablet.

[0136] "Pharmaceutically acceptable carriers" refer to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

[0137] The pharmaceutical composition is in the form of injection, capsule, tablet, pill, powder or granule.

[0138] There is no particular limitation on the administration of the compound or pharmaceutical composition of the present invention. Representative administration routes include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.

[0139] The dosage forms of the pharmaceutical composition of the present invention include (but are not limited to): injection, tablet, capsule, aerosol, suppository, film, pill, external ointment, controlled release or sustained release or nano preparation.

[0140] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

[0141] Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifying agents, and the release of the active compound or compounds in such compositions can be delayed in a certain portion of the digestive tract. Examples of useful encapsulating components are polymeric substances and waxes. If desired, the active compound can also be microencapsulated with one or more of the above-mentioned excipients.

[0142] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, or mixtures thereof.

[0143] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0144] Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances.

[0145] Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0146] Dosage forms for topical administration of the compounds of this invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.

[0147] The compounds of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds (such as anti-tumor drugs).

[0148] The treatment method of the present invention can be used alone or in combination with other treatment methods or therapeutic drugs.

[0149] The compounds of Formula I may be used in combination with other drugs known to treat or ameliorate similar conditions. When administered in combination, the original drug's route of administration and dosage can remain unchanged, while the compound of Formula I is administered simultaneously or subsequently. When the compound of Formula I is administered concurrently with one or more other drugs, a pharmaceutical composition containing both the one or more known drugs and the compound of Formula I may be preferably used. Combination administration also includes administering the compound of Formula I and one or more other known drugs during overlapping time periods. When the compound of Formula I is administered in combination with one or more other drugs, the dosage of the compound of Formula I or the known drug may be lower than when administered alone.

[0150] Drugs or active ingredients that can be used in combination with the compound of Formula I include, but are not limited to, gefitinib, erlotinib, icotinib, lapatinib, XL647, NVP-AEE-788, ARRY-334543, vandetanib, PF00299804, cetuximab, panitumumab, pertuzumab, zalutumumab, nimotuzumab, MDX-214, CDX-110, IMC-11F8, CNF2024, tanespiramycin, aspiramycin, IPI-504, and NVP-AUY922.

[0151] When using a pharmaceutical composition, a safe and effective amount of the compound of the present invention is administered to a mammal (e.g., a human or mouse) in need of treatment, wherein the dosage is a pharmaceutically effective dosage. For a 60 kg human, the daily dosage is generally 1 to 2000 mg, preferably 50 to 1000 mg. Of course, the specific dosage will also take into account factors such as the route of administration and the patient's health condition, all of which are within the skill of a skilled physician.

[0152] Compared with the prior art, the present invention has the following main advantages:

[0153] (1) The compounds of the present invention have excellent EGFR degradation performance;

[0154] (2) The compounds of the present invention have excellent inhibitory and / or therapeutic effects on EGFR-related diseases, especially diseases with EGFR drug-resistant mutations, including but not limited to diseases selected from the group consisting of H1975 (T790M / L858R), HCC827 (19DEL), and PC-9 (19DEL);

[0155] (3) The compounds of the present invention have excellent pharmacokinetic properties;

[0156] (4) The compounds of the present invention are suitable for preventing and / or treating diseases selected from the group consisting of: cancers with EGFR-sensitive mutations, and diseases that develop secondary drug resistance during current EGFR treatments;

[0157] (5) The compounds of the present invention have excellent safety.

[0158] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, were generally performed under conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0159] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those familiar to those skilled in the art. Furthermore, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred embodiments and materials described herein are for illustrative purposes only.

[0160] Example 1

[0161] Compounds synthesized by the present invention:

[0162] The experimental process is as follows:

[0163] 1. Synthesis of intermediate M1

[0164] The synthetic route is as follows:

[0165] Synthesis of intermediate M1

[0166] M1: Add 10g (1.0 equivalent) of compound SM1 to a 100ml single-necked flask, followed by a mixture of 43g (5.0 equivalents) of N,N-diisopropylethylamine and 100ml of isopropanol. Stir evenly at room temperature, then slowly add 12.2g (1.0 equivalent) of compound SM2 dropwise. After addition, replace the nitrogen atmosphere three times. Raise the temperature to reflux under nitrogen protection and stir overnight. Monitor the reaction until complete by a plate, evaporate the solvent under reduced pressure, add 50ml of ethyl acetate (EA), and stir at room temperature for 30 minutes. Filter with suction, rinse the filter cake twice with 15ml of ethyl acetate, and collect the filter cake, which is intermediate M1 (17.4g).

[0167] 2. Synthesis of intermediate M2

[0168] The synthetic route is as follows:

[0169] 1. Synthesis of Compound 2

[0170] In a 100ml three-necked flask, mix 200mg of compound 1 (1.0 equivalent), 138mg of cyclopropylboronic acid (2.0 equivalent), 167mg of potassium carbonate (1.5 equivalent), 4ml of 1,4-dioxane, and 0.8ml of water. Nitrogen was then added. 70mg of [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.12 equivalent) was added, and the temperature was raised to 100°C. The reaction was allowed to react overnight. TLC monitored the reaction until completion, and the mixture was filtered through a pad of Celite. The mother liquor was collected and the solvent removed by rotary evaporation. 30ml of water was added, and the mixture was extracted three times with 15ml of ethyl acetate. The combined organic phases were mixed and passed through a column chromatography column to yield 150mg of compound 2. LC-MS [M+1]: 212.

[0171] 2. Synthesis of compound 3

[0172] To a 50ml single-necked flask, add 120mg of compound 2 (1.0 equivalent), 160mg of N-boc-piperazine (1.5 equivalents), 235mg of potassium carbonate (3.0 equivalents), and 2.5ml of N,N-dimethylformamide. Under nitrogen, heat to 110°C and react overnight. Monitor the reaction by TLC until completion. Extract with ethyl acetate, dry over anhydrous sodium sulfate, spin dry, and column chromatography to yield 100mg of compound 3. LC-MS [M+1]: 478.

[0173] 3. Synthesis of compound 4

[0174] In a 50ml round-bottom flask, compound 3 (100mg, 1.0eq) was dissolved in 3ml of ethanol. Zinc powder (82mg, 6.0eq.), ammonium chloride (112mg, 10.0eq.), and water (0.6ml) were added. The reaction mixture was refluxed at 90°C overnight. LCMS confirmed the reaction was complete. The reaction mixture was directly washed with 500mg of silica gel (100-200mesh) and purified by column chromatography (EA in PE from 0% to 75%) to obtain the desired product 4 (60mg, yellow oil). LC-MS [M+1]: 348.

[0175] 4. Synthesis of intermediate M2

[0176] To a 50 ml single-necked flask, add compound 4 (60 mg, 1.0 eq), intermediate M1 (51 mg, 1.0 eq), p-toluenesulfonic acid monohydrate (40 mg, 1.2 eq), and 4 ml of isopropanol. Mix thoroughly, reflux overnight, and complete the reaction by LCMS. Adjust the pH to >7 by adding saturated sodium bicarbonate solution. Extract with ethyl acetate, wash the organic phase with saturated brine, and dry over anhydrous sodium sulfate. Add 500 mg of silica gel (100-200 mesh) and purify by column chromatography (MeOH in DCM 0% to 20%) to obtain the desired product M2 (50 mg, brown solid). LC-MS [M+1]: 508.

[0177] 3. Synthesis of intermediate M3

[0178] The synthetic route is as follows:

[0179] 1. Synthesis of Compound 2

[0180] In a 250ml three-necked flask, 5g of compound 1 was mixed with 10.8g of n-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester, 60ml of tetrahydrofuran, 24ml of methanol, 12ml of water, 6.8g of sodium carbonate, and 0.43g of PdCl2dppf. After nitrogen replacement, the temperature was raised to 80°C and the reaction was allowed to react overnight. TLC monitored the reaction until completion. The mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, and separated by column chromatography to obtain 5.8g of compound 2. LC-MS [M+1]: 275.

[0181] 2. Synthesis of compound 3

[0182] In a 100-ml three-necked flask, 5.1 g of compound 2, 7.1 g of 3-bromopiperidine-2,6-dione, and 7.2 g of N,N-diisopropylethylamine were dissolved in 51 ml of 1,4-dioxane. The temperature was raised to 100°C and the reaction was allowed to react overnight. TLC was used to monitor the reaction until completion. The product was extracted with dichloromethane, dried over anhydrous sodium sulfate, and then separated by column chromatography to obtain 3.6 g of compound 3. LC-MS [M+1]: 386.

[0183] 3. Synthesis of compound 4

[0184] 3.6 g of compound 2, 0.72 g of palladium carbon, and 36 ml of anhydrous ethanol were added to an autoclave, and the hydrogen pressure was increased to 0.7 MPa. The mixture was reacted for two days, filtered, and the solvent was removed by rotary evaporation to obtain 1.2 g of compound 4. LC-MS [M+1]: 388.

[0185] 4. Synthesis of Compound 5

[0186] To a 100 ml single-necked flask, add 1.2 g of compound 4 and dissolve in 30 ml of methanol. Cool in an ice-water bath and add dropwise a 4 M solution of dioxane hydrochloride. After addition, react at 40°C for 2 hours. Remove the solvent by rotary evaporation to obtain 1.4 g of compound 5. LC-MS [M+1]: 288.

[0187] 5. Synthesis of Compound 6

[0188] To a 100ml single-necked flask, add 0.8g of compound 5, 8ml of N-dimethylformamide, N-diisopropylethylamine, and tert-butyl bromoacetate and stir at room temperature overnight. TLC confirmed the reaction was complete. The mixture was extracted with ethyl acetate and water. The organic phase was dried, filtered, and purified by column chromatography to yield 300mg of compound 6. LC-MS [M+1]: 402.

[0189] 6. Synthesis of Compound M3

[0190] In a 100 ml single-necked flask, 100 mg of compound 6 and 1 ml of dichloromethane were added dropwise, and 1.6 ml of trifluoroacetic acid was added dropwise. The mixture was stirred at room temperature overnight. The reaction was complete as determined by TLC. The solvent was removed by rotary evaporation to obtain 150 mg of M3, LC-MS [M-1]: 344.

[0191] 4. Synthesis of Compound T-001

[0192] The synthetic route is as follows:

[0193] Compounds M2 (50 mg, 1.0 eq) and M3 (70 mg, 1.0 eq) were dissolved in 2 ml of NN-dimethylformamide in a 50 ml round-bottom flask and cooled to 0°C in an ice-water bath. NN-diisopropylethylamine (0.2 ml, 10.0 eq) and HATU (50 mg, 1.3 eq) were added with stirring. The mixture was reacted in an ice-water bath under nitrogen for 1 hour. The mixture was allowed to warm to room temperature naturally. TLC confirmed the reaction was complete. The mixture was extracted with ethyl acetate and water. The organic phase was dried, filtered, and purified by column chromatography to obtain 15 mg of compound T-001. LC-MS [M+1]: 833. HNMR: 1H NMR (400MHz, DMSO-d6) δ11.67(s,1H),10.79(s,1H),8.74(q,J=4.6Hz,1H),8. 65–8.45(m,1H),8.25(s,1H),8.12(s,1H),7.71(dd,J=8.0,1.6Hz,1H),7.27(d ,J=8.1Hz,1H),7.04(t,J=7.6Hz,1H),6.73(s,1H),6.62(d,J=8.1Hz,2H),5.71 (d,J=7.7Hz,1H),4.37(t,J=5.1Hz,0H),4.32–4.22(m,1H),3.75(s,3H),3.71( s,5H),3.50–3.39(m,5H),3.17(d,J=5.1Hz,0H),3.05(t,J=4.8Hz,2H),2.98(s ,2H),2.83–2.67(m,4H),2.60(ddd,J=17.6,14.1,4.4Hz,1H),2.22(td,J=8.4, 4.4Hz, 1H), 2.09 (dq, J=13.4, 4.7Hz, 1H), 1.85 (ddd, J=25.7, 12.8, 8.0Hz, 7H), 1.06(t,J=7.0Hz,1H), 0.88(dd,J=8.2,5.5Hz,2H), 0.53(q,J=5.1,4.6Hz,2H).

[0194] Example 2

[0195] Compounds synthesized by the present invention:

[0196] The experimental process is as follows:

[0197] 1. Synthesis of intermediate M1

[0198] The synthetic route is as follows:

[0199] Intermediate M1 was synthesized according to the method of Example 1

[0200] 2. Synthesis of intermediate M2

[0201] The synthetic route is as follows:

[0202] 1. Synthesis of Compound 2

[0203] In a 100ml three-necked flask, 500mg of compound 1 (1.0 equivalent), 536mg of vinyl boron trifluoride (2.0 equivalent), 165mg of potassium carbonate (1.5 equivalent), 5ml of 1,4-dioxane, and 1ml of water were mixed thoroughly under nitrogen. 175mg of [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.12 equivalent) was added, and the temperature was raised to 100°C. The reaction was allowed to react overnight. TLC was used to monitor the reaction until completion. The mixture was filtered through a pad of Celite, and the mother liquor was collected. The solvent was removed by rotary evaporation, followed by the addition of 30ml of water and extraction with 15ml of ethyl acetate three times. The combined organic phases were mixed and passed through a column chromatography column to yield 320mg of compound 2.

[0204] 2. Synthesis of compound 3

[0205] In a 100 ml single-necked flask, 320 mg of compound 2, 600 mg of N-boc-piperazine, and 666 mg of potassium carbonate were dissolved in 30 ml of DMF. The temperature was raised to 110°C and the reaction was carried out for 18 h. The solvent was removed by rotary evaporation. The residue was added with water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and then evaporated to dryness. Column chromatography was performed to obtain 400 mg of compound 3. LC-MS [M+1]: 366.

[0206] 3. Synthesis of compound 4

[0207] In a 100 ml single-necked bottle, 300 mg of compound 3 and 15 mg of palladium carbon were added to 5 ml of methanol and reacted at room temperature for 18 h. The mixture was filtered through a celite pad and the mother liquor was collected, dried over anhydrous sodium sulfate, and then spin-dried. Column chromatography was performed to obtain 250 mg of brown solid compound 4. LC-MS [M+1]: 336.

[0208] 4. Synthesis of intermediate M2

[0209] To a 50 ml single-necked flask, add compound 4 (223 mg, 1.0 eq), intermediate M1 (250 mg, 1.0 eq), p-toluenesulfonic acid monohydrate (156 mg, 1.2 eq), and 4 ml of isopropanol. Mix thoroughly, reflux overnight, and complete the reaction by LCMS. Adjust the pH to >7 by adding saturated sodium bicarbonate aqueous solution. Extract with ethyl acetate, wash the organic phase with saturated brine, and dry over anhydrous sodium sulfate. Mix with silica gel (100-200 mesh) and purify by column chromatography (MeOH in DCM 0% to 20%) to obtain the desired product M2 (130 mg, brown solid). LC-MS [M+1]: 496.

[0210] 3. Synthesis of intermediate M3

[0211] The synthetic route is as follows:

[0212] 1. Synthesis of Compound 2

[0213] In a 50ml three-necked flask, compound 1 (0.20g, 8.5mmol, 1.0eq) and TEA (2.58g, 25.5mmol, 3.0eq) were dissolved in 20ml of DMF and cooled to 0°C. (Tf)2O (3.6g, 12.76mmol, 1.5eq) was added to the mixture. The reaction mixture was allowed to warm to room temperature and stirred overnight. Completion of the reaction was monitored by TLC (potassium permanganate). The reaction mixture was evaporated to dryness, and the crude product was purified by column chromatography (100% PE) to obtain crude compound 2 as a yellow solid (841mg, 45.6% yield). LC-MS[M+1]: 368. 1H NMR (400MHz, DMSO-d6) δ6.84 (s, 1H), 4.24 (q, J = 4.4Hz, 3H), 4.05 (t, J = 11.3Hz, 3H), 1.43 (s, 12H).

[0214] 2. Synthesis of compound 3

[0215] 4-Aminophenylboronic acid pinacol ester (367 mg, 3.16 mmol, 1.2 eq), compound 2 (700 mg, 1.9 mmol, 1.0 eq), and sodium carbonate (607 mg, 5.73 mmol, 3.0 eq) were added to a 50 ml three-necked flask. The atmosphere was replaced with N2 three times, followed by the addition of dioxane (7 ml) and water (1.75 ml). The mixture was replaced with N2 three times, followed by the addition of Pd(dppf)Cl2 (140 mg, 0.19 mmol, 0.1 eq). The reaction mixture was stirred at 55°C under N2 protection for 2 h. TLC showed the disappearance of the starting material and the formation of new spots. The reaction mixture was filtered and the filtrate was evaporated to dryness. The crude product was purified by column chromatography (EA in PE from 0% to 40%) to afford compound 3 (230 mg, 32.4% yield) as a white solid. LC-MS [M+1]: 311.

[0216] 3. Synthesis of compound 4

[0217] In a 50 ml round-bottom flask, compound 3 (230 mg, 0.74 mmol, 1.0 eq) and 3-bromopiperidine-2,6-dione (171 mg, 0.89 mmol, 1.2 eq) were dissolved in 2.3 ml of N,N-dimethylformamide. Sodium bicarbonate (125 mg, 0.65 mmol, 2.0 eq) was added to the mixture. The reaction mixture was stirred at 70°C under nitrogen for 16 hours. After cooling to room temperature, the reaction was complete as determined by TLC. The reaction mixture was diluted with EA (10 ml), separated by addition of water (10 ml), and the aqueous phase was extracted with EA (10 ml). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the crude product was purified by column chromatography (EA in PE from 0% to 50%) to obtain compound 4 (60 mg, 19% yield). LC-MS [M+1]: 422.

[0218] 4. Synthesis of Compound 5

[0219] In a 500ml round-bottom flask, compound 4 (70mg, 0.16mmol, 1.0eq) was dissolved in 1ml of methanol. Palladium on carbon (7mg) was added to the mixture. The reaction mixture was stirred at room temperature under a balloon of H₂ for 16 hours. LCMS confirmed the reaction was complete. The reaction mixture was filtered to obtain crude compound 5 (70mg, 100% crude). LC-MS [M+1]: 424.

[0220] 5. Synthesis of Compound 6

[0221] In a 50-ml round-bottom flask, compound 5 (70 mg, 0.16 mmol, 1.0 eq) was dissolved in 2 ml of dichloromethane. Trifluoroacetic acid (0.5 ml) was added to the mixture. The reaction mixture was stirred at room temperature for 2 hours. LCMS confirmed the reaction was complete. The reaction mixture was evaporated to dryness to yield compound 6 (54 mg, 100% crude). LC-MS [M+1]: 324.

[0222] 6. Synthesis of Compound 7

[0223] In a 50 ml round-bottom flask, compound 6 (54 mg, 0.17 mmol, 1.0 eq) and tert-butyl bromoacetate (40 mg, 0.2 mmol, 1.2 eq) were dissolved in 1 ml of N,N-dimethylformamide. DIPEA (65 mg, 0.5 mmol, 3.0 eq) was added to the mixture. The reaction mixture was stirred at room temperature for 12 h. TLC confirmed the reaction was complete. The reaction mixture was diluted with EA (5 ml), separated by addition of water (5 ml), and the aqueous phase was extracted with EA (5 ml). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the crude product was purified by column chromatography (EA in PE from 0% to 60%) to obtain compound 7 (45 mg, 61.6% yield). LC-MS [M+1]: 438.

[0224] 7. Synthesis of Compound M3

[0225] In a 50-ml round-bottom flask, compound 7 (45 mg, 0.1 mmol, 1.0 eq) was dissolved in 2 ml of dichloromethane. Trifluoroacetic acid (0.5 ml) was added to the mixture. The reaction mixture was stirred at room temperature for 2 hours. LCMS confirmed the reaction was complete. The reaction mixture was evaporated to dryness to obtain compound M3 (45 mg, 100% crude). LC-MS [M+1]: 382.

[0226] 3. Synthesis of Compound T-009

[0227] The synthetic route is as follows:

[0228] Compounds M2 and M3 were dissolved in 2 ml of NN-dimethylformamide in a 50 ml round-bottom flask and cooled to 0°C in an ice-water bath. NN-diisopropylethylamine and HATU were added with stirring. The mixture was reacted in an ice-water bath under nitrogen for 1 hour. The temperature was naturally raised to room temperature. The reaction was determined to be complete by TLC. The mixture was extracted with ethyl acetate and water. The organic phase was dried, filtered, and purified by column chromatography to obtain 100 mg of compound T-009, LC-MS [M+1]: 860.

[0229] The following compounds were synthesized according to the method of Example 2:

[0230] Example 3

[0231] Compounds synthesized by the present invention:

[0232] The experimental process is as follows:

[0233] 1. Synthesis of intermediate M1

[0234] The synthetic route is as follows:

[0235] 1. Synthesis of Compound 2

[0236] Imidazole (587 mg, 1.2 eq) and 20 ml of tetrahydrofuran were added to a 100 ml three-necked flask and stirred to dissolve. The temperature was then lowered to 0°C. Sodium hydride (400 mg, 1.4 eq) was added portionwise to the reaction mixture. The mixture was stirred for 30 minutes. Compound 1 was added and allowed to warm to room temperature. The temperature was then raised to 60°C and the reaction was allowed to react overnight. TLC confirmed the reaction was complete. Excess sodium hydride was quenched with water, and the reaction mixture was extracted with ethyl acetate. The organic phase was mixed with silica gel and passed through a column to collect 260 mg of the desired component.

[0237] 2. Synthesis of compound 3

[0238] Compound 2 (260 mg, 1.0 eq), palladium-carbon catalyst (13 mg, 5 wt%), and 5 ml of methanol were added to a 50 ml single-necked flask and mixed thoroughly. The mixture was then replaced with a hydrogen balloon three times, and the pressure was maintained at room temperature for 20 hours. TLC indicated complete reaction. The reaction was then filtered through a celite pad, and the mother liquor was collected to yield 160 mg of compound 3.

[0239] 3. Synthesis of intermediate M1

[0240] Add 160 mg (1.0 equivalent) of compound 3 to a 100 ml single-necked flask, followed by a mixture of 0.8 ml (5.0 equivalents) of N,N-diisopropylethylamine and 2 ml of isopropanol. Stir evenly at room temperature, then slowly add 183 mg (1.0 equivalent) of trichloropyrimidine dropwise. After addition, replace the nitrogen atmosphere three times. Raise the temperature to reflux under nitrogen protection and stir overnight. Upon completion of the reaction, monitor the reaction with a plate, evaporate the solvent under reduced pressure, add 50 ml of ethyl acetate (EA), stir at room temperature for 30 minutes, filter, and rinse the filter cake twice with 15 ml of ethyl acetate. Collect the filter cake, which is intermediate M1 (180 mg).

[0241] 2. Synthesis of intermediate M2

[0242] The synthetic route is as follows:

[0243] 1. Synthesis of intermediate M2

[0244] To a 50ml single-necked flask, add intermediate M1 (70mg, 1.0eq), SM3 (70mg, 1.0eq), p-toluenesulfonic acid monohydrate (52mg 1.2eq), and 4ml of isopropanol. Mix thoroughly, reflux overnight, and complete the reaction by LCMS. Adjust the pH to >7 by adding saturated sodium bicarbonate solution. Extract with ethyl acetate, wash the organic phase with saturated brine, and dry over anhydrous sodium sulfate. Mix with silica gel (100-200 mesh) and purify by column chromatography (MeOH in DCM 0% to 20%) to obtain the desired product M2 (40mg, brown solid). LC-MS [M+1]: 479.

[0245] 3. Synthesis of Compound T-005

[0246] The synthetic route is as follows:

[0247] In a 50 ml round-bottom flask, intermediates M2 and M3 were dissolved in 2 ml of NN-dimethylformamide and cooled to 0°C in an ice-water bath. NN-diisopropylethylamine and HATU were added with stirring. The mixture was reacted in an ice-water bath under nitrogen for 1 hour. The mixture was allowed to warm to room temperature naturally. The reaction was complete as determined by TLC. The mixture was extracted with ethyl acetate and water. The organic phase was dried, filtered, and purified by column chromatography to obtain 20 mg of compound T-005. LC-MS [M+1]: 805; HNMR: 1H NMR (400MHz, DMSO-d6) δ10.84(s,1H),10.26(s,1H),8.54(d,J=8.5Hz,1H),8.32(s,2H),8.18(s,2 H),7.98(dd,J=8.2,1.6Hz,1H),7.52(d,J=8.6Hz,1H),7.41(t,J=7.8Hz,1H),7.31(t,J=7.8Hz,1H) ,7.03(d,J=8.0Hz,2H),6.77(d,J=2.5Hz,1H),6.68(d,J=8.1Hz,2H),6.56(dd,J=8.7,2.5Hz,1H), 5.76(s,1H),4.33(dd,J=9.7,5.1Hz,1H),3.85(s,3H),3.73(s,5H),3.29(s,3H),3.20(s,3H),2.79 (td,J=12.1,6.1Hz,2H),2.65(d,J=4.4Hz,1H),2.20–2.10(m,2H),1.99–1.76(m,5H),1.33(s,2H).

[0248] The following compounds were synthesized according to the method of Example 3:

[0249] Example 4

[0250] Compounds synthesized by the present invention:

[0251] The experimental process is as follows:

[0252] 1. Synthesis of intermediate M1

[0253] The synthetic route is as follows:

[0254] Intermediate M1 was synthesized according to the method of Example 1

[0255] 2. Synthesis of intermediate M2

[0256] The synthetic route is as follows:

[0257] 1. Synthesis of Compound 2

[0258] In a 100 ml single-necked flask, compound 1 (1.0 g, 1.0 eq) was mixed with pinacol diboron (1.18 g, 1.2 eq), 15 ml of 1,4-dioxane, potassium acetate (911 mg, 3.0 eq), and PdCl2dppf (113 mg, 0.12 eq). After nitrogen purge, the mixture was heated to 85°C and allowed to react overnight. TLC monitored the reaction until completion. The mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, and separated by column chromatography to yield 1.2 g of compound 2. LC-MS [M+1]: 372.

[0259] 2. Synthesis of compound 3

[0260] In a 100ml three-necked flask, 400mg of compound 2 (1.2 equivalents), 484mg of SM1 (1.0 equivalents), 345mg of potassium carbonate (3.0 equivalents), 10ml of 1,4-dioxane, and 2.5ml of water were mixed thoroughly under nitrogen. 80mg of [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.12 equivalents) was added, and the temperature was raised to 55°C for 2 hours. The reaction was monitored by TLC until completion, filtered through a pad of Celite, and the mother liquor was collected. The solvent was removed by rotary evaporation, followed by addition of 30ml of water and extraction three times with 15ml of ethyl acetate. The combined organic phases were mixed and passed through a column chromatography column to yield 500mg of compound 3. LC-MS [M+1]: 462.

[0261] 3. Synthesis of compound 4

[0262] Compound 3 (500 mg, 1.0 eq), palladium-carbon catalyst (50 mg, 5 wt%), and 5 ml of methanol were added to a 50 ml single-necked flask and mixed thoroughly. The mixture was then replaced with a hydrogen balloon three times, and the pressure was maintained at room temperature for 20 hours. TLC indicated complete reaction. The reaction was then filtered through a celite pad, and the mother liquor was collected to yield 400 mg of compound 4.

[0263] 4. Synthesis of Compound 5

[0264] To a 100 ml single-necked flask, add 400 mg of compound 4 and dissolve in 10 ml of tetrahydrofuran. Cool in an ice-water bath and add dropwise a 4 M solution of dioxane hydrochloride. After addition, react at 40°C for 2 hours. Remove the solvent by rotary evaporation to obtain 330 mg of compound 5. LC-MS [M+1]: 364.

[0265] 5. Synthesis of Compound 6

[0266] To a 100 ml single-necked flask, 330 mg of compound 5, 4 ml of NN-dimethylformamide, 1.2 ml of NN-diisopropylethylamine (5.0 eq), and tert-butyl bromoacetate (195 mg, 1.1 eq) were added and stirred at room temperature overnight. TLC confirmed the reaction was complete, and the mixture was extracted with ethyl acetate and water. The organic phase was dried, filtered, and purified by column chromatography to yield 370 mg of compound 6. LC-MS [M+1]: 479.

[0267] 6. Synthesis of intermediate M2

[0268] In a 100 ml single-necked flask, 350 mg of compound 6 and 3 ml of dichloromethane were added dropwise, and 2 ml of trifluoroacetic acid was added dropwise. The mixture was stirred at room temperature overnight. The reaction was detected to be complete by TLC. The solvent was removed by rotary evaporation to obtain 150 mg of M2, LC-MS [M-1]: 420.

[0269] 3. Synthesis of Compound T-013

[0270] The synthetic route is as follows:

[0271] Compounds M2 (150 mg, 1.0 eq) and M1 (176 mg, 1.0 eq) were dissolved in 4 ml of NN-dimethylformamide in a 50 ml round-bottom flask and cooled to 0°C in an ice-water bath. NN-diisopropylethylamine and HATU (176 mg, 1.3 eq) were added with stirring. The mixture was reacted in an ice-water bath under nitrogen for 1 hour. The temperature was naturally raised to room temperature. The reaction was determined to be complete by TLC. The mixture was extracted with ethyl acetate and water. The organic phase was dried, filtered, and purified by column chromatography to obtain 90 mg of compound T-013. LC-MS [M+1]: 899.6.

[0272] 1H NMR (400MHz, DMSO-d6) δ11.69(s,1H),10.64(s,1H),8.80(s,1H),8.70–8.54(m,1H),8.29(s,1H),8.21(s,1H),7. 76(d,J=7.8Hz,1H),7.71–7.52(m,3H),7.38(s,1H),7.13(q,J=8.5,7.6Hz,2H),6.88(s,1H),4.12–3.93(m,6H),3. 79(d,J=18.4Hz,5H),3.68(s,3H),3.53–3.51(m,1H),3.20(d,J=7.6Hz,2H),3.10(s,1H),2.98(s,2H),2.93–2.78 (m,8H),2.69(d,J=7.4Hz,1H),2.33(d,J=12.9Hz,1H),2.05(s,1H),1.94(d,J=13.0Hz,1H),1.16(t,J=7.6Hz,3H).

[0273] The following compounds were synthesized by referring to the method of Example 4:

[0274] Example 5

[0275] Compounds synthesized by the present invention:

[0276] The experimental process is as follows:

[0277] 1. Synthesis of intermediate M1

[0278] The synthetic route is as follows:

[0279] Intermediate M1 was synthesized according to the method of Example 1

[0280] 2. Synthesis of intermediate M2

[0281] The synthetic route is as follows:

[0282] 1. Synthesis of Compound 2

[0283] In a 100ml three-necked flask, 500mg of compound 1 (1.0 equivalent), 536mg of vinyl boron trifluoride (2.0 equivalent), 165mg of potassium carbonate (1.5 equivalent), 5ml of 1,4-dioxane, and 1ml of water were mixed thoroughly under nitrogen. 175mg of [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.12 equivalent) was added, and the temperature was raised to 100°C. The reaction was allowed to react overnight. TLC was used to monitor the reaction until completion. The mixture was filtered through a pad of Celite, and the mother liquor was collected. The solvent was removed by rotary evaporation, followed by the addition of 30ml of water and extraction with 15ml of ethyl acetate three times. The combined organic phases were mixed and passed through a column chromatography column to yield 320mg of compound 2.

[0284] 2. Synthesis of compound 3

[0285] In a 100 ml single-necked flask, 320 mg of compound 2, 600 mg of N-boc-piperazine, and 666 mg of potassium carbonate were dissolved in 30 ml of DMF. The temperature was raised to 110°C and the reaction was carried out for 18 hours. The solvent was removed by rotary evaporation. The residue was added with water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and then evaporated to dryness. Column chromatography was performed to obtain 400 mg of compound 3. LC-MS [M+1]: 366.

[0286] 3. Synthesis of compound 4

[0287] In a 100 ml single-necked bottle, 300 mg of compound 3, 3 ml of hydrogen chloride / tetradioxane, and 5 ml of dichloromethane were mixed and reacted at room temperature for 6 h. The reaction solution was evaporated to dryness under reduced pressure to obtain 217 mg of yellow solid compound 4. LC-MS [M+1]: 264.

[0288] 4. Synthesis of Compound 5

[0289] In a 100 ml single-necked bottle, 217 mg of compound 4 was dissolved in 3 ml of dichloromethane. 202 mg of DMAP was added and the mixture was allowed to react at room temperature for 5 min. 346 mg of trifluoroacetic anhydride was then added and the mixture was allowed to react at room temperature for 18 h. The reaction solution was evaporated to dryness under reduced pressure to obtain 295 mg of yellow solid compound 5. LC-MS [M+1]: 360.

[0290] 5. Synthesis of Compound 6

[0291] In a 100-ml single-necked flask, 295 mg of compound 5 was dissolved in 5 ml of ethanol and 1 ml of water. 320 mg of zinc powder and 435 mg of solid ammonium chloride were added. The mixture was refluxed at 100°C for 4 h. The zinc powder was filtered through a celite pad. The mother liquor was evaporated under reduced pressure to remove the solvent. Column chromatography was performed to obtain 100 mg of compound 6. LC-MS [M+1]: 330.

[0292] 6. Synthesis of Compound 7

[0293] To a 50 ml single-necked flask, 100 mg of compound 6, 90 mg of M1, 347 mg of trifluoroacetic acid, and 3 ml of isopropanol were added. The mixture was refluxed at 100°C for 18 h. The reaction mixture was quenched with saturated sodium bicarbonate solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, and spin-dried. The mixture was purified by column chromatography to obtain 111 mg of compound 7 as a yellow solid. LC-MS [M+1]: 590.

[0294] 7. Synthesis of intermediate M2

[0295] To a 50 ml single-necked flask, add compound 7 (111 mg, 1.0 eq), potassium hydroxide (105 mg, 10.0 eq), 5 ml of methanol, and 1 ml of water. Mix well and heat to 60°C for 4 h. LCMS confirms the reaction is complete. Quench the reaction mixture with water. Extract with dichloromethane, wash the organic phase with saturated brine, and dry over anhydrous sodium sulfate. Mix with silica gel (100-200 mesh) and purify by column chromatography (MeOH in DCM 0% to 10%) to obtain the desired product M2 (60 mg, brown solid). LC-MS [M+1]: 493.

[0296] 3. Synthesis of Compound T-003

[0297] The synthetic route is as follows:

[0298] In a 50mL round-bottom flask, 60mg of compound M2 and 87mg of SM1 were dissolved in 3ml of NN-dimethylformamide and cooled to 0°C in an ice-water bath. 1ml of NN-diisopropylethylamine and 48mg of HATU were added with stirring. The mixture was reacted in an ice-water bath under nitrogen for 1 hour. The temperature was naturally raised to room temperature and the reaction was allowed to proceed for 2 hours. The reaction was complete as determined by TLC. The mixture was extracted with ethyl acetate and water. The organic phase was dried, filtered, and purified by column chromatography to obtain 100mg of compound T-003. LC-MS [M+1]: 821.1H NMR (400MHz, DMSO-d6) δ11.75(s,1H),10.86(s,1H),8.86(d,J=4.8Hz,1H),8.63(s,1H),8.43(s,1H),8.20(s,1H),7.83– 7.72(m,2H),7.29(s,1H),7.13–6.96(m,4H),6.81(s,1H),6.65(d,J=8.6Hz,2H),5.74(d,J=7.5Hz,1H),5.59(d,J=17.8H z,1H),5.18(d,J=11.3Hz,1H),4.32(ddd,J=11.8,7.4,4.8Hz,1H),3.84(s,5H),3.72(s,2H),3.28(s,2H),2.97(d,J=32. 9Hz, 6H), 2.85 (d, J = 4.5Hz, 3H), 2.65 (d, J = 4.4Hz, 1H), 2.20–1.84 (m, 5H), 1.77 (d, J = 11.9Hz, 2H), 1.66 (d, J = 12.6Hz, 2H).

[0299] Example 6

[0300] Compounds synthesized by the present invention:

[0301] The experimental process is as follows:

[0302] 1. Synthesis of intermediate M1

[0303] The synthetic route is as follows:

[0304] 1. Synthesis of Compound 2

[0305] In a 50ml three-necked flask, 4-piperidone (1.06g, 6.9mmol, 1.1eq) and DIPEA (2.4g, 18.6mmol, 3.0eq) were dissolved in 10ml of DMF. 3,4-Difluoronitrobenzene (1g, 6.29mmol, 1.0eq) was added to the mixture. The atmosphere was replaced with nitrogen three times, and the mixture was stirred at 110°C overnight. TLC monitored the reaction until completion. The reaction mixture was diluted with EA (10ml) and stirred for 5 minutes. Water (10ml) was added, and the mixture was allowed to stand for separation. The aqueous phase was extracted once with EA (10ml). The combined organic phases were washed with saturated NaCl (15ml x 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was spun down to dryness. The crude product was purified by column chromatography (EA in PE from 0% to 40%) to obtain crude compound 2 as a yellow solid (629mg, 42% yield). LC-MS [M+1]: 239.

[0306] 2. Synthesis of compound 3

[0307] Add tert-butyl acetate (367 mg, 3.16 mmol, 1.2 eq) to a 100 ml three-necked flask. After replacing the atmosphere with N2 three times, add anhydrous tetrahydrofuran (10 ml). Cool the mixture to -78°C, slowly add LDA to the reaction system, and stir at -78°C for 45 min. Dissolve tert-butyl acetate (367 mg, 3.16 mmol, 1.2 eq) in anhydrous tetrahydrofuran (10 ml) and slowly add dropwise to the reaction system. Stir the reaction at -78°C for 2 h. TLC shows the disappearance of the starting material and the formation of new spots. Quench the reaction by adding sat. aq. NH4Cl (10 ml). Add EA to the mixture and allow the mixture to stand for separation. Wash the organic phase with saturated brine (10 ml x 3), dry over anhydrous sodium sulfate, filter, and spin-dry. The crude product was purified by column chromatography (EA in PE from 0% to 40%) to give yellow solid compound 3 (781 mg, 83.2% yield). LC-MS [M+1]: 355.

[0308] 3. Synthesis of compound 4

[0309] In a 100ml three-necked flask, compound 3 (781mg, 2.2mmol, 1.0eq), ammonium chloride (1.4g, 21.87mmol, 10.0eq), and iron powder (741mg, 13.2mmol, 6.0eq) were dispersed in 10ml of a 4:1 ethanol:water solution. The mixture was replaced with nitrogen three times and the temperature was raised to reflux for 18h. TLC indicated the disappearance of the starting material, and the solvent was removed by rotary evaporation. The crude product was purified by column chromatography (EA in PE from 0% to 50%) to afford compound 4 (669mg, 93.6% yield) as a yellow solid. LC-MS [M+1]: 325.

[0310] 4. Synthesis of Compound 5

[0311] In a 100 ml round-bottom flask, compound 4 (669 mg, 2.06 mmol, 1.0 eq) and 3-bromopiperidine-2,6-dione (595 mg, 3.09 mmol, 1.5 eq) were dissolved in 6.69 ml of N,N-dimethylformamide. Sodium bicarbonate (347 mg, 4.13 mmol, 2.0 eq) was added to the mixture. The reaction mixture was stirred at 70°C under nitrogen for 16 hours. After cooling to room temperature, the reaction was complete as determined by TLC. The reaction mixture was diluted with EA (10 ml), separated by addition of water (100 ml), and the aqueous phase was extracted with EA (10 ml). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the crude product was purified by column chromatography (EA in PE from 0% to 57%) to obtain compound 5 (570 mg, 63.6% yield). LC-MS [M+1]: 436.

[0312] 5. Synthesis of Compound M1

[0313] In a 50-ml round-bottom flask, compound 5 (290 mg, 0.667 mmol, 1.0 eq) was dissolved in 3 ml of dichloromethane. Trifluoroacetic acid (0.5 ml) was added to the mixture. The reaction mixture was stirred at room temperature for 2 hours. LCMS confirmed the reaction was complete. The reaction mixture was evaporated to dryness to obtain compound M1 (253 mg, 100% crude). LC-MS [M+1]: 381.

[0314] 2. Synthesis of Compound T-037

[0315] The synthetic route is as follows:

[0316] 1. Synthesis of Compound M2 Reference Example 2

[0317] 2. Synthesis of T-037

[0318] In a 50ml round-bottom flask, compounds M1 (253mg, 0.66mmol, 1.0eq) and M2 (330mg, 0.66mmol, 1.0eq) were dissolved in 3.3ml of N,N-dimethylformamide. N,N-diisopropylethylamine (258mg, 1.98mmol, 3.0eq) was added to the mixture. The reaction mixture was cooled to 0°C in an ice-water bath under nitrogen protection. HATU (304mg, 0.8mmol, 1.2eq) was added to the reaction mixture with stirring and allowed to react in an ice-water bath under nitrogen protection for 2 hours. The mixture was allowed to warm to room temperature naturally. The reaction was complete by TLC. The reaction mixture was diluted with EA (10ml), stirred with water (10ml) for 5 minutes, and allowed to stand for separation. The aqueous phase was extracted with EA (10ml). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the crude product was purified by column chromatography (MeOH in DCM from 0% to 3%) to obtain compound T-037 (295 mg, 51.69% yield). LC-MS [M+1]: 857.1H NMR (400MHz, DMSO-d6) δ11.63(s,1H),10.81(s,1H),8.76(q,J=4.6Hz,1H),8.57(d,J=8.2Hz,1H),8.19(d,J=31.9Hz,2H),7.84–7.62(m,1H ),7.50(s,1H),7.32(t,J=7.8Hz,1H),7.08(t,J=7.5Hz,1H),6.84(d,J=20.3Hz,2H),6.51(dd,J=15.0,2.5Hz,1H),6.42(dd,J=8.8,2.5Hz, 1H),5.81(s,1H),4.91(s,1H),4.26(dt,J=12.6,6.2Hz,1H),3.74(d,J=24.6Hz,7H),2.99–2.82(m,7H),2.80(d,J=4.4Hz,3H),2.74(s,1H) ,2.66–2.53(m,5H),2.09(dq,J=13.4,4.8Hz,1H),1.92–1.73(m,3H),1.69(d,J=12.4Hz,2H),1.24(d,J=8.0Hz,1H),1.09(t,J=7.4Hz,3H).

[0319] The following compounds were synthesized by the method of Example 6:

[0320] Example 7

[0321] Compounds synthesized by the present invention:

[0322] The experimental process is as follows:

[0323] 1. Synthesis of intermediate M3

[0324] 1. The synthesis of intermediate M2 refers to Example 2.

[0325] 2. Synthesis of Compound 2

[0326] To a 50 mL three-necked flask, weigh 600 mg of M2 and dissolve it in 6 mL of DMF. Then, add 188 mg of Al and 469 mg of DIPEA. After purging with N2 three times, react at 90°C overnight. TLC monitoring revealed the formation of new spots. The reaction solution was added with water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and purified by column chromatography to yield 448 mg of compound 2. LC-MS [M+1]: 540.

[0327] 3. Synthesis of intermediate M3

[0328] In a 50 mL single-necked flask, 448 mg of compound 2 and 252 mg of DIPEA were dissolved in 5 mL of DCM. 206 mg of A2 was dissolved in 2 mL of DCM and slowly added dropwise to the reaction mixture. After three N2 ventilations, the mixture was allowed to react at room temperature for 2 h. The reaction was monitored by TLC until compound 2 ceased to decrease. The reaction mixture was then directly dried under reduced pressure and subjected to column chromatography to yield 286 mg of intermediate M3. LC-MS [M+1]: 694.

[0329] 2. Synthesis of Compound T-023

[0330] The experimental process is as follows:

[0331] In a 50 ml round-bottom flask, 186 mg of compound M3 and 119 mg of A3 were dissolved in 3 mL of acetonitrile, and then 82 mg of KI and 159 mg of DIPEA were added. After N2 ventilation three times, the reaction was carried out at 75°C for 3 h. The reaction was complete after TLC detection. The reaction solution was dried under reduced pressure and the sample was mixed and subjected to column chromatography to obtain 190 mg of compound T-023. LC-MS [M+1]: 809.1H NMR (400MHz, DMSO-d6) δ11.72(s,1H),10.87(s,1H),8.90(q,J=4.6Hz,1H),8.63(d,J=8.5Hz,1H),8.28(s,1H),8.20(s,1H), 7.82(d,J=7.9Hz,1H),7.54(s,1H),7.37(t,J=8.0Hz,1H),7.14(t,J=7.6Hz,1H),7.04(d,J=8.2Hz,2H),6.86(s,1H),6.70(d ,J=8.3Hz,2H),5.82(d,J=8.9Hz,1H),4.35(ddd,J=11.9,7.5,4.8Hz,1H),3.83(s,3H),3.23(s,1H),2.96(t,J=4.7Hz,5H),2 .86(d,J=4.5Hz,4H),2.84–2.69(m,6H),2.64(q,J=7.5Hz,4H),2.00–1.82(m,4H),1.57–1.23(m,6H),1.14(t,J=7.5Hz,3H).

[0332] The following compounds were synthesized according to the method of Example 7:

[0333] Example 8

[0334] Compounds synthesized by the present invention:

[0335] The experimental process is as follows:

[0336] 1. Synthesis of intermediate M1

[0337] The synthetic route is as follows:

[0338] 1. Synthesis of Compound 2

[0339] In a 50ml three-necked flask, 1-tert-Butyloxycarbonylpiperazine (0.5g, 3.14mmol, 1.0eq) and potassium carbonate (1300mg, 9.42mmol, 3.0eq) were added to 5ml of DMF. 3,4-Difluoronitrobenzene (877mg, 4.71mmol, 1.5eq) was added to the mixture. The atmosphere was replaced with nitrogen three times, and the mixture was stirred at 90°C overnight. TLC monitored the reaction until completion. The reaction mixture was diluted with EA (10ml) and stirred for 5 minutes. Water (10ml) was added, and the mixture was allowed to stand for separation. The aqueous phase was extracted once with EA (10ml). The combined organic phases were washed with saturated NaCl (15ml x 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was spun down to dryness. The crude product was purified by column chromatography (EA in PE from 0% to 40%) to afford crude compound 2 as a yellow solid (1.13g, 110% yield). LC-MS[M+1]:326.

[0340] 2. Synthesis of compound 3

[0341] In a 50 ml three-necked flask, compound 2 (1.13 g, 3.47 mmol, 1.0 eq), ammonium chloride (445 mg, 6.95 mmol, 2.0 eq), and iron powder (584 mg, 10.4 mmol, 3.0 eq) were dispersed in 12.5 ml of a 5:1 ethanol:water mixture. The mixture was heated to reflux and allowed to react for 4 h. TLC indicated the disappearance of the starting material. The solvent was removed by rotary evaporation, and the crude product was purified by column chromatography (EA in PE from 0% to 40%) to afford compound 3 (946 mg, 92.3% yield) as a colorless oil. LC-MS [M+1]: 151.

[0342] 3. Synthesis of compound 4

[0343] In a 50 ml round-bottom flask, compound 3 (946 mg, 3.2 mmol, 1.0 eq) and 3-bromopiperidine-2,6-dione (923 mg, 4.8 mmol, 1.5 eq) were dissolved in 10 ml of N,N-dimethylformamide. Sodium bicarbonate (538 mg, 6.4 mmol, 2.0 eq) was added to the mixture. The reaction mixture was stirred at 70°C under nitrogen for 16 hours. After cooling to room temperature, the reaction was complete as determined by TLC. The reaction mixture was diluted with EA (10 ml), separated by addition of water (10 ml), and the aqueous phase was extracted with EA (10 ml). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the crude product was purified by column chromatography (EA in PE from 0% to 55%) to obtain compound 4 (798 mg, 61.4% yield). LC-MS [M+1]: 407.

[0344] 4. Synthesis of Compound 5

[0345] In a 50-ml round-bottom flask, compound 4 (798 mg, 1.96 mmol, 1.0 eq) was dissolved in 10 ml of dichloromethane. Trifluoroacetic acid (2 ml) was added to the mixture. The reaction mixture was stirred at room temperature for 2 hours. LCMS confirmed the reaction was complete. The reaction mixture was evaporated to dryness to yield compound 5 (600 mg, 100% crude). LC-MS [M+1]: 307.

[0346] 5. Synthesis of Compound 6

[0347] In a 50 ml round-bottom flask, compound 5 (300 mg, 1.96 mmol, 1.0 eq) and tert-butyl bromoacetate (460 mg, 2.36 mmol, 1.2 eq) were dissolved in 6 ml of N,N-dimethylformamide. DIPEA (761 mg, 5.9 mmol, 3.0 eq) was added to the mixture. The reaction mixture was stirred at room temperature for 12 h. TLC confirmed the reaction was complete. The reaction mixture was diluted with EA (10 ml), separated by addition of water (10 ml), and the aqueous phase was extracted with EA (10 ml). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the crude product was purified by column chromatography (EA in PE from 0% to 70%) to obtain compound 6 (707 mg, 85.6% yield). LC-MS [M+1]: 421.

[0348] 6. Synthesis of Compound 7 (i.e., M1)

[0349] In a 50-ml round-bottom flask, compound 6 (300 mg, 0.71 mmol, 1.0 eq) was dissolved in 3 ml of dichloromethane. Trifluoroacetic acid (1 ml) was added to the mixture. The reaction mixture was stirred at room temperature for 2 hours. LCMS confirmed the reaction was complete. The reaction mixture was evaporated to dryness to obtain compound M1 (260 mg, 100% crude). LC-MS [M+1]: 365.

[0350] 2. Synthesis of T-029

[0351] 1. Synthesis of Compound M2 Reference Example 2

[0352] 2. Synthesis of T-029

[0353] In a 50ml round-bottom flask, compound 7 (260mg, 0.71mmol, 1.0eq) and M2 (352.6mg, 0.0.71mmol, 1.0eq) were dissolved in 3ml of N,N-dimethylformamide. N,N-diisopropylethylamine (276mg, 2.14mmol, 3.0eq) was added to the mixture. The reaction mixture was cooled to 0°C in an ice-water bath under nitrogen protection. HATU (325mg, 0.85mmol, 1.2eq) was added to the reaction mixture with stirring and allowed to react in an ice-water bath under nitrogen protection for 2 hours. The mixture was allowed to warm to room temperature naturally. The reaction was complete by TLC. The reaction mixture was diluted with EA (10ml), stirred with water (10ml) for 5 minutes, and allowed to stand for separation. The aqueous phase was extracted with EA (10ml). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the crude product was purified by column chromatography (MeOH in DCM from 0% to 3%) to obtain compound T-029 (244 mg, 40.73% yield). LC-MS [M+1]: 842.36. 1H NMR (400MHz, DMSO-d6) δ11.63(s,1H),10.81(s,1H),8.75(q,J=4.6Hz,1H),8.57(d,J=8.4Hz,1H),8.22(s,1H),8.14(s,1H),7.71(d,J=7.9Hz,1 H),7.51(s,1H),7.31(t,J=7.9Hz,1H),7.06(t,J=7.6Hz,1H),6.84(d,J=9.4Hz,1H),6.80(s,1H),6.52(dd,J=15.0,2.5Hz,1H),6.41(dd,J=8.8 ,2.5Hz,1H),5.84(d,J=7.7Hz,1H),3.74(d,J=14.5Hz,5H),3.64(s,1H) ,3.29(d,J=9.3Hz,1H),2.89(s,5H),2.85–2.78(m,6H),2.73(td,J=12. 3,6.1Hz,2H),2.62(q,J=7.1Hz,6H),2.08(dq,J=13.3,4.7Hz,1H),1.85(qd,J=12.3,4.7Hz,1H),1.23(d,J=10.7Hz,1H),1.09(t,J=7.5Hz,3H).

[0354] Example 9

[0355] Compounds synthesized by the present invention:

[0356] The synthetic route is as follows:

[0357] 1. Synthesis of intermediate M1

[0358] 1. Synthesis of Compound 2

[0359] Compound 1 (500 mg, 1.0 eq) and 2 ml of methanol were added to a 100 ml three-necked flask and stirred to dissolve. Glyoxal (960 mg, 2.0 eq) was added to the reaction mixture, mixed thoroughly, cooled to 0°C, and aqueous ammonia (4 ml) was added. The mixture was allowed to warm to room temperature and allowed to react overnight. After TLC analysis of the reaction, the reaction mixture was extracted with ethyl acetate, and the organic phase was passed through a silica gel column to collect 330 mg of the desired fraction. LC-MS [M+1]: 190.

[0360] 2. Synthesis of compound 3

[0361] Compound 2 (330 mg, 1.0 eq), palladium-carbon catalyst (16 mg, 5 wt%), and 5 ml of methanol were added to a 50 ml single-necked flask and mixed thoroughly. The mixture was then replaced with a hydrogen balloon three times, and the pressure was maintained at room temperature for 20 hours. TLC indicated complete reaction. The reaction was completed. The mother liquor was collected and purified by column chromatography to yield 230 mg of compound 3. LC-MS [M+1]: 160.

[0362] 3. Synthesis of intermediate M1

[0363] 230 mg (1.0 equivalent) of compound 3 was added to a 100 ml single-necked flask, followed by a mixture of 1.3 ml (5.0 equivalents) of N,N-diisopropylethylamine and 2 ml of isopropanol. Stirring was continued at room temperature, followed by the dropwise addition of 530 mg (2.0 equivalents) of trichloropyrimidine. After addition, the nitrogen atmosphere was replaced three times, the temperature was raised to reflux under nitrogen protection, and stirring was continued overnight. Upon completion of the reaction, the solvent was evaporated under reduced pressure, and the residue was added to 50 ml of ethyl acetate (EA). The mixture was stirred at room temperature for 30 minutes, filtered, and the filter cake was rinsed twice with 15 ml of ethyl acetate. The filter cake was collected to obtain 300 mg of intermediate M1. LC-MS [M+1]: 305.

[0364] 2. Synthesis of intermediate M2

[0365] To a 50ml single-necked flask, add intermediate M1 (150mg, 1.0eq), SM3 (150mg, 1.0eq), p-toluenesulfonic acid monohydrate (112mg, 1.2eq), and 4ml of isopropanol. Mix thoroughly, reflux overnight, and complete the reaction by LCMS. Adjust the pH to >7 by adding saturated sodium bicarbonate solution. Extract with ethyl acetate, wash the organic phase with saturated brine, and dry over anhydrous sodium sulfate. Mix with silica gel (100-200 mesh) and purify by column chromatography (MeOH in DCM 0% to 20%) to obtain the desired product M2 (100mg, brown solid). LC-MS [M+1]: 476.

[0366] 3. Synthesis of Compound T-011

[0367] The synthetic route is as follows:

[0368] In a 50 ml round-bottom flask, intermediates M2 and M3 were dissolved in 2 ml of NN-dimethylformamide and cooled to 0°C in an ice-water bath. NN-diisopropylethylamine and HATU were added with stirring. The mixture was reacted in an ice-water bath under nitrogen for 1 hour. The temperature was naturally raised to room temperature. The reaction was complete as determined by TLC. The mixture was extracted with ethyl acetate and water. The organic phase was dried, filtered, and purified by column chromatography to obtain 33 mg of compound T-011, LC-MS [M+1]: 804.

[0369] The following compounds were synthesized by the method of Example 9:

[0370] Example 10

[0371] Compounds synthesized by the present invention:

[0372] 1. Synthesis of intermediate M1

[0373] 1. Synthesis of Compound 2

[0374] To a 100ml three-necked flask, add compound 1 (1g, 1.0eq), formamidine acetate (1.15g, 2.0eq), and 15ml of ethylene glycol monomethyl ether. Heat to 100°C and allow to react overnight. After TLC, adjust the pH to >7 with saturated sodium bicarbonate solution. Extract the reaction solution with ethyl acetate, and pass the organic phase through a silica gel column to collect 720mg of the desired fraction.

[0375] 2. Synthesis of compound 3

[0376] Compound 2 (720 mg, 1.0 eq), palladium-carbon catalyst (36 mg, 5 wt%), and 10 ml of methanol were added to a 50 ml single-necked flask and mixed thoroughly. The mixture was then replaced with a hydrogen balloon three times, and the pressure was maintained at room temperature for 20 hours. TLC indicated complete reaction. The reaction was completed. The mother liquor was collected and purified by column chromatography to yield 450 mg of compound 3. LC-MS [M+1]: 162.

[0377] 3. Synthesis of intermediate M1

[0378] 300 mg (1.0 equivalent) of compound 3 was added to a 100 ml single-necked flask, followed by a mixture of 1.6 ml (5.0 equivalents) of N,N-diisopropylethylamine and 5 ml of isopropanol. Stirring was continued at room temperature, followed by the dropwise addition of 682 mg (2.0 equivalents) of trichloropyrimidine. After addition, the nitrogen atmosphere was replaced three times, the temperature was raised to reflux under nitrogen protection, and stirring was continued overnight. Upon completion of the reaction, the solvent was evaporated under reduced pressure, and the residue was added to 50 ml of ethyl acetate (EA). The mixture was stirred at room temperature for 30 minutes, filtered, and the filter cake was rinsed twice with 15 ml of ethyl acetate. The filter cake was collected to obtain 250 mg of intermediate M1. LC-MS [M+1]: 307.

[0379] 2. Synthesis of intermediate M2

[0380] To a 50ml single-necked flask, add intermediate M1 (250mg, 1.0eq), SM3 (250mg, 1.0eq), p-toluenesulfonic acid monohydrate (184mg, 1.2eq), and 4ml of isopropanol. Mix thoroughly, reflux overnight, and complete the reaction by LCMS. Adjust the pH to >7 by adding saturated sodium bicarbonate solution. Extract with ethyl acetate, wash the organic phase with saturated brine, and dry over anhydrous sodium sulfate. Mix with silica gel (100-200 mesh) and purify by column chromatography (MeOH in DCM 0% to 20%) to obtain the desired product M2 (60mg, brown solid). LC-MS [M+1]: 507.

[0381] 3. Synthesis of Compound T-076

[0382] The synthetic route is as follows:

[0383] In a 50 ml round-bottom flask, intermediate M2 (60 mg, 1.0 eq) and M3 were dissolved in 2 ml of NN-dimethylformamide and cooled to 0°C in an ice-water bath. NN-diisopropylethylamine and HATU were added with stirring. The mixture was reacted in an ice-water bath under nitrogen for 1 hour. The mixture was allowed to warm to room temperature naturally. The reaction was complete as determined by TLC. The mixture was extracted with ethyl acetate and water. The organic phase was dried, filtered, and purified by column chromatography to obtain 11 mg of compound T-076. LC-MS [M+1]: 834.6; 1H NMR (400MHz, DMSO-d6) δ12.57(s,1H),12.52(s,1H),10.86(s,1H),8.80(s,1H),8.55(s,1H),8.27(d,J=1.7Hz,1H),8.18(s,1H),7.58( s,1H),7.51(d,J=8.1Hz,1H),7.32(d,J=8.1Hz,1H),7.02(d,J=8.1Hz,2H),6.89(s,1H),6.66(d,J=8.1Hz,2H),5.74(d,J=7.5Hz,1H),4. 37–4.28(m,1H),3.89–3.76(m,5H),3.73(s,2H),3.57(s,1H),3.09(s,2H),3.00(s,2H),2.92(s,2H),2.73(q,J=7.5Hz,3H),2.45(s,2H ),2.27(s,2H),2.19–2.10(m,2H),2.06(d,J=1.9Hz,1H),1.93(dd,J=12.4,8.1Hz,2H),1.80(s,2H),1.72(s,2H),1.21(t,J=7.5Hz,3H).

[0384] Comparative Example 1 Control Compound 1

[0385] The experimental process is as follows:

[0386] 1. Synthesis of intermediate M1

[0387] The synthetic route is as follows:

[0388] Intermediate M1 was synthesized according to the method of Example 1

[0389] 2. Synthesis of intermediate M2

[0390] The synthetic route is as follows:

[0391] Intermediate M2 was synthesized according to the method of Example 1

[0392] 3. Synthesis of Reference Compound 1

[0393] The synthetic route is as follows:

[0394] Compounds M2 and M3 were dissolved in 2 ml of NN-dimethylformamide in a 50 ml round-bottom flask, cooled to 0°C in an ice-water bath, and NN-diisopropylethylamine and HATU were added with stirring. The mixture was reacted in an ice-water bath under nitrogen for 1 hour, and then naturally warmed to room temperature. The reaction was complete when detected by TLC. The mixture was extracted with ethyl acetate and water, and the organic phase was dried, filtered, and purified by column chromatography to obtain 50 mg of reference compound 1. LC-MS [M+1]: 783; HNMR: 1H NMR (400MHz, DMSO-d6) δ11.83(s,1H),10.79(s,1H),8.77(s,1H),8.36(s,1H),8.16(s,1H),8.04(d,J=8.0Hz,1H),7.37(d,J =10.4Hz,2H),7.06(t,J=7.6Hz,1H),6.95(d,J=8.1Hz,2H),6.76–6.68(m,2H),6.57(dd,J=16.5,7.3Hz,3H),5.67(d,J=7.5Hz ,1H),4.25(s,0H),3.77(s,5H),3.64(s,2H),3.23(s,4H),3.14(s,2H),2.94(s,2H),2.78–2.70(m,0H),2.67(s,3H),2.58(d ,J=4.3Hz,0H),2.34(s,1H),2.15–2.03(m,3H),1.85(dt,J=12.2,6.1Hz,1H),1.72(d,J=11.7Hz,2H),1.58(d,J=12.3Hz,2H).

[0395] Test of compound's cell growth inhibitory activity

[0396] Test Example 1 Cell Anti-Proliferation Experiment

[0397] 1. Experimental materials and equipment:

[0398] H1975 has an EGFR T790M / L858R double mutation, PC-9 has an EGFR exon 19 deletion, and HCC827 has an exon 19 deletion mutation. CellCounting-Lite 2.0, Trypsin EDTA, 37°C CO2 incubator, cell counter, EnVision Serial No. 1050454.

[0399] 2. Experimental preparation:

[0400] 1. 96-well plate plating

[0401] A) Logarithmic phase cells were digested with Trypsin EDTA, the reaction was terminated by adding culture medium, and the cells were mixed by pipetting to prepare a cell suspension.

[0402] B) Use Vi-cell to determine the cell concentration and prepare a suspension of 15,000-25,000 cells per ml based on the experimental purpose and cell characteristics.

[0403] C) After the cell suspension is prepared, mix gently and add 100 μl to each well so that the cell density to be measured is 1500-2500 per well.

[0404] 2. Compound treatment

[0405] Compound dilution

[0406] A) Weigh approximately 2 mg of compound and calculate the required volume of DMSO according to the formula: compound mass (mg) * compound purity (%) / compound molecular weight * 1000

[0407] B) The inoculated cell culture plate is placed in an incubator and cultured for about 24 hours, and compounds with gradient concentrations are added.

[0408] C) Dilute 10 mM compound stock solution to 50 mM with culture medium, add 50 mM compound solution to the second column of the deep-well plate, and add 375 ml of culture medium containing 0.5% DMSO to the third to eleventh columns.

[0409] D) Serial dilution: Pipette 125 μl of solution from the second column and add it to the third column. Mix thoroughly. Then, pipette 125 μl of solution from the third column and add it to the fourth column. Repeat this process until the tenth column.

[0410] E) Using a multichannel pipette, pipette 25 μL of compound from the deep-well plate and add it to a 96-well plate. Repeat three times for each compound in the 96-well plate. Finally, a 1:4 concentration gradient is formed with a maximum concentration of 10,000 nM on the 96-well plate.

[0411] 3. Add CTG and read the reading

[0412] A) The 96-well plate was incubated in an incubator for 72 hours, and the effects of the compounds were observed under an inverted microscope.

[0413] B) Add 25 μl of CTG solution to each well, place on a shaker for 10 minutes, and read the OD value of each well.

[0414] 4. Data Analysis

[0415] The following formula was used to calculate the cell viability (% Cell Viability):

[0416] %Cell Viability=100%×(Lum_Sample-Lum_LC) / (Lum_HC-Lum_LC)

[0417] Lum_HC: 0.1% DMSO control group cell readings

[0418] Lum_Sample: Cell readout with added compound

[0419] Lum_LC: Blank culture medium reading

[0420] The IC50 values ​​were obtained by curve fitting using GraphPad Prism 8 software.

[0421] As shown in Table 1, AA≤10nM; 10nM <A≤100nM;100nM<B<1000nM;C≥1000nM。

[0422] Table 1

[0423] As can be seen from Table 1, the compounds of the present invention have very good inhibitory effects on H1975 (human lung adenocarcinoma cells), PC-9 (human lung cancer cells), and HCC827 (human non-small cell lung cancer cells).

[0424] Experimental Example 2 EGFR PROTAC HTRF Experiment

[0425] 1. Instruments and reagents

[0426] Among them, Baf3-19del-T780M-C797S is a stable Ba / F3 clone expressing exogenous EGFR gene bearing T790M, C797S and L858R triple amino acid mutations, purchased from Kangyuan Bochuang; Baf3-L858R-T780M-C797S is a stable Ba / F3 clone expressing exogenous EGFR gene bearing exon19 E746_A750 deletion, T790M, C797S triple mutations, purchased from Kangyuan Bochuang.

[0427] 2. Experimental steps

[0428] 1) Cell preparation:

[0429] 2) Reagent preparation:

[0430] Dilute Eu and d2 antibody 20 times with detection buffer at a rate of 2 μl antibody per well, and then mix the two antibodies.

[0431] 3) Detection:

[0432] 3. Results and calculation

[0433] Open EnVision, find the HTRF program, set up the plate, and then read the plate.

[0434] Use GraphPad Prism to generate the fitting curve, DC50 and Dmax of the compound.

[0435] As shown in Table 2, for DC50, AA ≤ 10 nM; 10 nM < A ≤ 100 nM; 100 nM < B < 1000 nM; C ≥ 1000 nM; for Dmax, 70% ≤ A ≤ 100%; 50% ≤ B < 70%; C < 50%; NA means not tested.

[0436] Table 2

[0437] Among them, BAF3-DTC: Baf3-19del-T780M-C797S is a Stable Ba / F3 clone expressing exogenous EGFR gene bearing T790M, C797S and L858R triple amino acid mutations, purchased from Kangyuan Bochuang; BAF3-LTC: Baf3-L858R-T780M-C797S is a Stable Ba / F3 clone expressing exogenous EGFR gene bearing exon19 E^{746}_A^{750} deletion, T790M, C797S triple mutations, purchased from Kangyuan Bochuang.

[0438] It can be seen from Table 2 that the compound of the present invention has excellent degradation performance for EGFR cells containing L858R-T780M-C797S triple mutations and 19del-T780M-C797S triple mutations.

[0439] Pharmacokinetic study of the compound

[0440] Test Example 3 Pharmacokinetic test of male SD rats

[0441] 1.1 Experimental animals

[0442] Three healthy adult male SD rats, 6-8 weeks old, weighing 200-300 g were used.

[0443] 1.2 Equipment and Reagents

[0444] 1.2.1 Equipment

[0445] Analytical balance, animal weighing scale, magnetic stirrer, gavage needle, refrigerated centrifuge, single-channel manual pipette, liquid chromatography-mass spectrometry, etc.

[0446] 1.2.2 Reagents

[0447] EDTA-Na2 anticoagulant: Weigh 11.2 g of EDTA-Na2 into a reagent bottle. Add 100 mL of normal saline and vortex to dissolve completely. Once prepared, aliquot into 1.5 mL centrifuge tubes, each containing approximately 20 μL, for whole blood sample collection.

[0448] 2 Experimental process

[0449] 2.1 Drug preparation

[0450] Accurately weigh approximately 10 mg of the sample to be tested and dissolve it in DMSO (10% of the total volume). Slowly add 0.5% MC solvent (90% of the total volume) while stirring. Ultrasonicate and vortex mix to obtain a visually uniform solution of the preparation at a concentration of 1 mg / mL. Prepare freshly before use.

[0451] A 0.2 mL sample was taken into a 1.5 mL centrifuge tube and stored at -80°C for concentration analysis of the dosing solution.

[0452] 2.2 Animal Preparation

[0453] Animals were housed in rat cages and fasted for at least 10 hours, but not water, starting the day before the experiment. On the day of the experiment, each animal was weighed and tail-marked. Blank blood was collected from each animal before dosing. Blood was collected from the tail vein.

[0454] 2.3 Administration

[0455] Route of administration: oral administration (po)

[0456] Dosing concentration: 1mg / ml

[0457] Dosage: 10 mg / kg

[0458] Dosing volume: 10mL / kg

[0459] Operation procedure: Use your left hand wearing a bite-proof glove to catch the rat, make it stand upright, insert the gavage needle into the mouth and throat, and try to insert the needle when there is no obvious resistance, and then inject the drug into the stomach.

[0460] 2.4 Sample collection

[0461] At 0.5, 1, 2, 4, 6, 8, 12, and 24 hours after administration, 0.1-0.2 ml of whole blood was collected from the animals in EDTA-Na2 anticoagulant tubes. The tubes were inverted 3-4 times to mix thoroughly. The supernatant plasma was separated by centrifugation at 2000 g for 5 minutes at 4°C and promptly transferred to -80°C for storage until testing. Blood was collected from the tail vein.

[0462] 3. Sample analysis and data processing

[0463] 3.1 Sample analysis

[0464] Using Shimadzu liquid phase and Triple Quad TM 6500 + A quantitative assay for the test compound was established using AB mass spectrometry. The concentration of the unchanged drug in plasma was analyzed. The results were controlled for variation using quality control samples, which should have an accuracy between 80% and 120%.

[0465] 3.2 Data processing

[0466] The main pharmacokinetic parameters were calculated using the non-compartmental model in Winnonlin Phoenix software, including the area under the concentration-time curve (AUC(0-t) and AUC(0-∞)), elimination half-life (T 1 / 2 ), maximum plasma concentration (C max ), time to reach maximum plasma concentration (T max ))wait.

[0467] The results are shown in Table 3.

[0468] Table 3

[0469] It can be seen from Table 3 that the compounds of the present invention have better pharmacokinetic effects than the control compound 1.

[0470] All documents mentioned herein are incorporated by reference herein to the same extent as if each document were individually incorporated by reference. It should be understood that, after reading the above teachings, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents are within the scope of the appended claims.

Claims

1. A compound, characterized in that The compound is a compound of formula I, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotope compound or prodrug thereof, in: L is selected from the following group: Ring A is selected from the following group: Ring B is selected from the group consisting of: In various Each X1 and X2 are independently selected from the following group: CR, N; Each X3 is independently selected from the group consisting of NH, O, and none; Each Ar is independently selected from the group consisting of substituted or unsubstituted phenyl, substituted or unsubstituted 5-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S, The substitution is refers to being substituted by one or more (such as 2, 3 or 4) substituents selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, hydroxy substituted C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl-NH-, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 3-6 Halogenated cycloalkyl, cyano, oxo, -C(O)NR9R 10 、-CO-C 1-6 Alkyl, -CO-C 3-6 Cycloalkyl, -CO-C 1-6 Haloalkyl, -CO-C 3-6 Halogenated cycloalkyl, 5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S; Each R1 is independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl, cyano; Each R2 and R3 are independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkyl-NH-, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Haloalkyl, cyano, C3-6 halocycloalkyl, -NR9C(O)R 10 、-C(O)NR9R 10 , methylsulfonyl, Unsubstituted or C 1-6 Alkyl-substituted 5-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S; Each R4 is independently selected from the following group: C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl; Each R5 is independently selected from the group consisting of: absent, C 1-6 Alkyl, NR, Each R6, R7, R8 is independently selected from the following group: H, halogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl-NH-, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Haloalkyl, cyano, C 3-6 Halogenated Cycloalkyl-NR9C(O)R 10 、-C(O)NR9R 10 , methylsulfonyl, Hydroxyl, or R6 and the ring to which it is connected form a 3-6 membered ring; Each R9 is independently selected from the group consisting of H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl; Each R 10 Independently selected from the group consisting of H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Haloalkyl, C 3-6 Halogenated cycloalkyl, methanesulfonyl, Each m, n, q is independently selected from the following group: 0, 1, 2, 3, 4, 5; Each R 11 Independently selected from the group consisting of H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl; Each R is independently selected from the group consisting of H, C 1-6 Alkyl, hydroxyl, halogen, C 1-6 Halogenated alkyl.

2. The compound according to claim 1, characterized in that Each Ar is independently selected from the group consisting of substituted phenyl, The substitution means substituted by a substituent selected from the group consisting of: -C(O)NR9R 10 , a 5-6 membered heteroaryl group containing 1, 2 or 3 N; R 11 , q as defined in claim 1; R9 is selected from the following group: H, C 1-6 alkyl; R 10 Selected from the following group: H, C 1-6 alkyl; And R9 and R 10 Not H at the same time.

3. The compound according to claim 1, characterized in that Each Ar is independently selected from the group consisting of substituted phenyl, The substitution refers to substitution by a substituent selected from the following group: -C(O)NR9R 10 , a 5-6 membered heteroaryl group containing 1, 2 or 3 N; R 11 , q as defined in claim 1; R9 is H; R 10 C 1-6 alkyl.

4. The compound according to claim 1, characterized in that R3 is selected from the following group: H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl.

5. The compound according to claim 1, characterized in that The compound is a compound represented by formula II, formula III, formula IV, formula V, formula VI or formula VII, Wherein R4 is a C selected from the following group 1-6 Alkyl: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, neopentyl, tert-pentyl, hexyl.

6. The compound according to claim 1, characterized in that The compound is selected from the group consisting of:

7. A pharmaceutical composition, characterized in that The invention comprises a safe and effective amount of the compound according to claim 1 and a pharmaceutically acceptable carrier.

8. A use of the compound according to claim 1, characterized in that For use selected from the group consisting of: 1) Preparation of drugs for regulating EGFR kinase activity or treating EGFR-related diseases; 2) Prepare drugs for degrading EGFR protein.

9. The use according to claim 8, characterized in that The EGFR-related disease is an EGFR drug-resistant mutation-related disease.

10. The use according to claim 8, characterized in that The EGFR-related disease is selected from the group consisting of inflammation, cancer, cardiovascular disease, infection, immune disease, and metabolic disease.

Citation Information

Patent Citations

  • Compounds which cause degradation of EGFR, for use against cancer

    WO2019149922A1

  • Isoindolinone and indazole compounds for the degradation of EGFR

    WO2021127561A1

  • Compound for EGFR (epidermal growth factor receptor) protein degradation and application thereof

    CN116135852A

  • EGFR (epidermal growth factor receptor) degradation agent

    CN116891502A

  • Degradation of (EGFR) by conjugation of EGFR inhibitors with e3 ligase ligand and methods of use

    WO2022012622A1